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                              1. INTRODUCTION 
    The oral drug administration has been the predominant route for drug 
delivery due to the ease of administration, patient convenience and flexibility in 
formulations. However, it is a well accepted fact today that drug absorption 
throughout the GI tract is not uniform. Using currently utilized release technology, 
oral drug delivery for 12 or even 24 hours is possible for many drugs that are 
absorbed uniformly from GI tract. Nevertheless this approach is not suitable for a 
variety of important drugs characterized by narrow absorption window in the upper 
part of GI tract i.e. stomach and small intestine. 
               The design of oral controlled drug delivery systems (DDS) should be 
primarily aimed to achieve the more predictability and reproducibility to control the 
drug release, drug concentration in the target tissue and optimization of the 
therapeutic effect of a drug by controlling its release in the body with lower and less 
frequent dose. 
 The controlled release systems for oral use are mostly solid and based on 
dissolution or diffusion or a combination of both the mechanisms in the control of 
release rate of drug. Depending upon the manner of drug release they are classified as 
follows 
1.1. CLASSIFICATION OF CONTROLLED DRUG DELIVERY SYSTEM [4, 27, 
37]
 
A. Continuous release system: These systems release the drug for a prolonged 
period of time along the entire length of GIT with normal transit of the dosage form. 
The various systems under this category are:  
I. Dissolution controlled release systems 
II. Diffusion controlled release systems 
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III. Dissolution and diffusion controlled release systems 
IV. Ion-Exchange resins – drug complexes  
V. slow dissolving salts and complexes 
VI. pH–dependent formulations 
VII. Osmotic pressure controlled systems 
VIII. Hydrodynamic pressure controlled systems 
B. Delayed transit and continuous release system: These systems are designed to 
prolong their residence in the GIT along with their release. Often, the dosage is 
fabricated to retain in the stomach and hence the drug present therein should be stable 
at gastric pH. Systems included in this category are:  
I. Altered density systems 
II. Mucoadhesive systems 
III. Size-based systems 
C. Delayed release systems: The design of such systems involve release of drug only 
at a specific site in the GIT. 
The drugs contained in such system have following category: 
 Destroyed in the stomach or by intestinal enzymes 
 Known to cause gastric distress 
 Absorbed from a specific intestinal site, or 
 Meant to exert local effect at a specific GI site. 
The two types of delayed release systems are: 
I. Intestinal release systems 
II. Colonic release systems 
Oral controlled release dosage forms have been developed for the past three 
decades due to their various benefit characteristics which includes. 
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Table No.1: Advantages 
                         Benefit of oral controlled-release drug delivery systems 
          Benefit                               Reason 
Therapeutic advantage Reduction in drug plasma level fluctuations; 
maintenance of a steady plasma level of the drug over 
a prolonged period, ideally simulating an intravenous 
infusion of a drug ref 
Reduction in adverse 
side effects and 
improvement in 
tolerability 
Drug plasma levels are maintained within a narrow 
therapeutic window with no sharp peaks and with 
AUC of plasma concentration versus time 
comparable with total AUC from multiple dosing 
with immediate release dosage form. 
Patient comfort and 
compliance 
Oral drug delivery is the most common and 
convenient for patients, and a reduction in dosing 
frequency enhances compliance. 
Reduction in health 
care cost 
The total cost of the controlled release product could 
be lower than the immediate release product. With 
reduction in side effects the overall expense in 
disease management also would be reduced. 
 
Despite several advantages associated with controlled drug delivery system, 
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Table No.2: Disadvantages  
               Disadvantages of oral controlled-release drug delivery systems 
       Disadvantage               Reason 
Over dose There is always possibility of sudden release of the total 
dose administered i.e. dose dumping, which may result 
in toxic manifestations. 
Less flexibility in dose 
adjustments 
The adjustment of dosage for controlled release dosage 
form is very difficult. The physician has less flexibility 
in adjusting the dosage regimens. 
Side effects Along with longer duration of action controlled release 
preparations shows long duration of side effects, 
especially if the patient is hypersensitive to the given 
medication. 
Cost The cost of unit dose of controlled therapeutic system is 
higher than the conventional dosage forms. 
 
To overcome these problems and improve the efficacy of oral administration, 
some recent studies have reported that controlled oral drug delivery system with 
prolonged gastric residence time, such as floating dosage system have been proved to 
be advantages. 
A gastrointestinal drug delivery system can be made to float in the stomach by 
a gelling process of hydrocolloid materials or by incorporating a floatation chamber 
with vacuum or gas. In this way bulk density less than that of gastric fluid is 
produced. However, most of the devices generating gas or gelling need time to be 
floated and this parameter must be checked carefully in order to prevent the dosage 
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form from transiting into the small intestine along with food before floating in 
stomach.  
1.2. GASTRO-RETENTIVE DOSAGE FORMS (GRDF):[1,5,12,14,15,50] 
 These are primarily controlled release drug delivery systems, which gets 
retained in the stomach for longer periods of time, thus helping in absorption of drug 
for the intended duration of time. Gastric retentive drug delivery devices can be useful 
for the spatial and temporal delivery of many drugs. 
The gastric emptying time mainly depends upon the design of the dosage form 
and physiological state of the subject, which last from a few minutes to 12 hrs. The 
average gastric emptying time in human is 2-3 hrs through major absorption zone 
(stomach and upper part of the intestine), which leads to incomplete drug release from 
the DDS leading to diminished efficacy of the administered dose. So drugs which 
have stability problem, GRDF plays an important role. These considerations have led 
to the development of oral controlled release dosage forms possessing gastric 
retention capabilities.                                                                                                                                
 GRDF will also greatly improve the pharmacotherapy of the stomach itself 
through local drug release leading to high drug concentrations at the gastric mucosa, 
which are sustained over a long period of time. 
1.2.1. Anatomy and Physiology of Stomach: [44] 
1.2.1. a) Anatomy: 
             The stomach is j- shaped organ located in the upper left hand portion of the 
abdomen just below the diaphragm. It occupies a portion of the epigastric and left 
hypochondriac region. The main function of the stomach is to store the food 
temporarily, grind it and then release it slowly into the duodenum. Due to its small 
surface area very little absorption takes place from the stomach.  
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                                   Figure No. 1: Anatomy of the stomach. 
The stomach has four main regions: 
1. Cardia  3. Body and 
2. Fundus         4. Pylorus 
              The main function of the fundus and body is storage, whereas that of cardia 
is mixing or grinding. The fundus adjusts the increased volume during eating by 
relaxation of the fundus muscle fibers. The fundus also exerts a steady pressure on the 
gastric contents pressing them towards the distal region, to pass through the pyloric 
sphincter into the small intestine. 
1.2.1. b) Physiology: 
                Various factors like absorption ability, presystemic clearance, gastric 
motility; gastrointestinal transit time and gastrointestinal emptying time will have an 
influence on the bioavailability of drug from the dosage form. 
Absorption ability: 
The absorption capability of various segments of gastrointestinal tract differs 
from each other. i.e. most of the absorption takes place in small intestine and lesser 
extent in colon and stomach. Unless drugs are absorbed equally in both the colon and 
in small intestine, the duration for most of the drugs is 3-8 hours. This will be the 
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major limiting factor for sustained release and controlled release drug delivery 
systems. 
Presystemic clearance: 
Even if the drugs that can be absorbed equally well throughout the 
gastrointestinal tract, bioavailability is significantly reduced by the site-specific 
changes in presystemic clearance. Degradation of the drug is also carried out by 
hydrolysis in the stomach, enzymatic digestion, and metabolism in the brush border of 
the gut wall and by the microorganisms. 
 Such degradation may leads to high variation in plasma drug concentration 
and poor absorption of drug in to the systemic circulation. 
Gastric motility: 
       Gastric emptying occurs during fasting as well as fed states. During the fasting 
state an interdigestive series of electrical events take place, which cycles through 
stomach and intestine every 2 to 3 hours. This is called the interdigestive myloelectric 
cycle or migrating myloelectric cycle (MMC), which is further divided into 4 phases 
as described by Wilson and Washington. 
After the ingestion of a mixed meal, the pattern of contractions changes from 
fasted to that of fed state. This is also known as digestive motility pattern and 
comprises continuous contractions as in phase II of fasted state. These contractions 
result in reducing the size of food particles (to less than 1 mm), which are propelled 
toward the pylorus in a suspension form. During the fed state onset of MMC is 
delayed resulting in slowdown of gastric emptying rate. Scintifc graphic studies 
determining gastric emptying rates revealed that orally administered controlled 
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release dosage forms are subjected to basically two complication, that of short gastric 
residence time and unpredictable gastric emptying rate. 
1. Phase I (basal phase) lasts from 40 to 60 minutes with rare 
contractions. 
2. Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent 
action and potential contractions. As the phase progresses the intensity 
and frequency also   increases gradually. 
3. Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and 
regular contractions for short period. It is due to this wave that all the 
undigested material is swept out of the stomach down to the small 
intestine. It is also known as the housekeeper wave. 
4. Phase IV lasts for 0 to 5 minutes and occurs between phases III and I 
of 2 consecutive cycles. 
Gastrointestinal Transit Time:       
  Food content remains in each segment of the gastrointestinal tract for 
different periods of time. The resident time for both liquid and solid foods in each 
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Table No.3: Transit time of food in each segment of the gastrointestinal tract 
Segment Liquid Solid 
Stomach 10-30min 1-3 hours 
Duodenum < 60sec < 60 sec 
Jejunum and ileum 3 hours ± 1.5 hours 4 hours ± 1.5 hours 
Colon ------------- 20-50 hours 
 
Since most of the drugs are absorbed from the upper part of intestine, the total 
effective time for the drug absorption is 3-8 hours. So one has to take most of the 
drugs 1-2 times a day. 
1.2.1.c) Factors affecting the gastric emptying time:[32] 
I. State of the stomach: gastric emptying time depends upon the fed state of the 
stomach, which increases the gastric emptying time as compared to unfed 
state. 
II. Circadian rhythms: which are increased in day time and less during night, also 
affects the gastric retention time (GRT).     
III. Size of the Meal: greater the energy content of the meal (carbohydrate and 
high fat content), longer the duration of emptying. 
IV. Density of the oral dosage form: The density of the gastric fluid is reported to 
be 1.2g/cm. The density of the dosage form should be less than this for the 
buoyancy so that it is retained in the stomach for longer period of time. 
V. Diseased state: State of the stomach also affects the environment for the 
dosage form as in case of ulcers, flatulence and spasms. 
VI. Drug therapy: Plays an important role in gastric emptying e.g. prokinetic drugs 
like cisapride and mosapride increase the gastric emptying time. 
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VII. Age: Increase in age decreases the gastric motility thereby increasing the 
gastric emptying time. 
VIII. Posture: It was seen that the supine posture on the right side showed better 
results than on the left side. 
1.2.1. d) Criteria for selection of drug candidate for GRDF: [32] 
The gastric retentive drug delivery systems are suitable for following types of 
drug therapy: 
I. Absorption from upper part of GIT: Drugs have a particular site for maximum 
absorption e.g. ciprofloxacin, whose maximum absorption is in the stomach 
only. The absorption of metformin hydrochloride is confirmed to small 
intestine only and the conventional sustained release dosage forms may be 
poorly bioavailable since absorption appears to diminish when the dosage 
form pass in to large intestine. 
II. Drugs having low pKa, which remains unionized in stomach for better 
absorption. 
III. Drugs having reduced solubility at higher pH e.g.captopril and 
chlordiazepoxide and the bioavailability of drugs that get degraded in alkaline 
pH can be increased by formulating gastro-retentive dosage forms. e.g. 
doxifluridine, which degrades in small intestine. 
IV. Local action as it is seen in the treatment of H.Pylori by amoxicillin and 
misoprostol for ulcers.  
V. To minimize gastric irritation this may be caused by sudden increase of drug 
concentration in the stomach. E.g. NSAIDs. 
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VI. Improve effectiveness of particular drugs. E.g. antibiotics in the colon tend to 
disturb the microflora causing overgrowth of microorganisms like Clostridium 
difficile causing colitis. 
1.3. GASTRO RETENTIVE DRUG DELIVERY SYSTEM: [55(b), 32, 45] 
                                                 
 Oral drug delivery is the most desirable and preferred method of 
administering therapeutic agents for their systemic effects. Oral medication is 
generally considered as the first avenue investigated in the development of 
pharmaceutical formulations because of patient acceptance, convenience in 
administration and cost effective manufacturing processes. Oral route offers an 
attractive approach of drug targeting at the specific site within GI tract for certain 
types of drug. 
1.3.1 Approaches to Gastric Retention: 
A number of approaches have been used to increase the GRT of a dosage form 
in stomach by employing a variety of concepts. These include: 
a) Floating Systems: [23] 
Floating Drug Delivery Systems (FDDS) have a bulk density lower than 
gastric fluids and thus remain buoyant in the stomach for a prolonged period of time, 
without affecting the gastric emptying rate. While the system is floating on the gastric 
contents, the drug is released slowly at a desired rate from the system. After the 
release of the drug, the residual system is emptied from the stomach. This results in an 
increase in the GRT and a better control of fluctuations in the plasma drug 
concentrations.  
Floating systems can be classified into two distinct categories, 
 (A) effervescent 
 (B) non-effervescent systems. 
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b) Bio/Muco-adhesive Systems: [27] 
Bio/Muco-adhesive systems are those which bind to the gastric epithelial 
surface or mucin and serve as a potential means of extending the GRT of drug 
delivery system (DDS) in the stomach. 
The surface epithelial adhesive properties of mucin have been well recognized 
and applied to the development of GRDS based on bio/muco-adhesive polymers. The 
ability to provide adhesion of a drug (or a delivery system) to the GI wall provides a 
longer residence time in a particular organ site, thereby producing an improved effect 
in terms of local action or systemic effect. 
Binding of polymers to the mucin/epithelial surface can be divided into three broad 
categories:  
1. Hydration-mediated adhesion. 
2. Bonding-mediated adhesion. 
3. Receptor-mediated adhesion. 
c) Swelling and Expanding Systems: 
                These are the dosage forms, which after swallowing; swell to an extent that 
prevents their exit from the pylorus. As a result, the dosage form is retained in the 
stomach for a longer. These systems may be named as “plug type system” since they 
exhibit the tendency to remain logged at the pyloric sphincter if that exceed a 
diameter of approximately 12-18 mm in their expanded state. Such polymeric 
matrices remain in the gastric cavity for several hours even in the fed state. 
            A balance between the extent and duration of swelling is maintained by the 
degree of cross-linking between the polymeric chains. A high degree of cross-linking 
retards the swelling ability and maintains its physical integrity for prolonged period. 
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d) High Density Systems 
These systems with a density of about 3 g/cm3 are retained in the rugae of the 
stomach and are capable of withstanding its peristaltic movements. A density of 2.6-
2.8 g/cm3 acts as a threshold value after which systems can be retained in the lower 
part of the stomach. High-density formulations include coated pellets. Coating is done 
by heavy inert materials such as barium sulphate, zinc oxide, titanium dioxide, and 
iron powder. 
e) Incorporation of Passage Delaying Food Agents: 
Food excipients like fatty acids e.g. salts of myristic acid change and modify 
the pattern of the stomach to a fed state, thereby decreasing gastric emptying rate and 
permitting considerable prolongation of release. The delay in the gastric emptying 
after meals rich in fats is largely caused by saturated fatty acids with chain length of 
C10-C14. 
f) Ion Exchange Resins: [33] 
A coated ion exchange resin bead formulation has been shown to have gastric 
retentive properties, which was loaded with bicarbonates. Ion exchange resins are 
loaded with bicarbonate and a negatively charged drug is bound to the resin. The 
resultant beads were then encapsulated in a semi-permeable membrane to overcome 
the rapid loss of carbon dioxide. Upon arrival in the acidic environment of the 
stomach, an exchange of chloride and bicarbonate ions take place, as a result of this 
reaction carbon dioxide was released and trapped in the membrane thereby carrying 
beads towards the top of gastric content and producing a floating layer of resin beads 
in contrast to the uncoated beads, which will sink quickly. 
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g) Osmotic Regulated Systems: 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a bioerodible capsule. In the stomach the capsule quickly 
disintegrates to release the intragastric osmotically controlled drug delivery device. 
The inflatable support inside forms a deformable hollow polymeric bag that contains a 
liquid that gasifies at body temperature to inflate the bag. The osmotic controlled drug 
delivery device consists of two components, drug reservoir compartment and 
osmotically active compartment. 
1.3.2 Types of Floating Drug Delivery Systems (FDDS): [16, 42] 
Based on the mechanism of buoyancy, two distinctly different technologies 
have been utilized in the development of FDDS, which are: 
A. Effervescent System 
    I. Gas generating system 
1. Gastric bilayered floating tablets 
2. Multiple unit type floating pills 
3. Multi-unit type oral floating  stages of floating mechanisam dosage 
system 
II. Volatile liquid/vacuum containing system 
1. Intragastric floating gastrointestinal drug delivery system 
2. Inflatable gastrointestinal delivery system 
3. Intragastric osmotically controlled drug delivery system 
B. Non- Effervescent System 
1. Single layer floating tablets 
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2. Alginate beads 
3. Hollow microspheres 
A.  Effervescent System: [2] 
Effervescent systems include use of gas generating agents, carbonates (sodium 
bicarbonate) and other organic acid (citric acid and tartaric acid) to produce carbon 
dioxide (CO2) gas, thus reducing the density of the system and making it to float on 
the gastric fluid. These effervescent systems further classified into two types. 
I. Gas Generating Systems: 
  Intra Gastric Single Layer Floating Tablet or Hydro dynamically Balanced System 
(HBS) 
                                     
                          Figure No. 2: hydro dynamically balanced system 
These are formulated by mixing the CO2 generating agents and the drug within 
the matrix tablet (Fig. 2). These have a bulk density lower than gastric fluids and 
therefore remain floating in the stomach unflattering the gastric emptying rate for a 
prolonged period. The drug is slowly released at a desired rate from the floating 
Chapter  1                                                                                                   
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system and after the complete release the residual system is expelled f
stomach. This leads to an increase in the GRT and a better control over fluctuations in 
plasma drug concentration.
1.  Intra Gastric Bilayered Floating Tablets:
These are also compressed tablet and contain
i) Immediate release layer 
                   Figure No. 3: Intra Gastric Bilayer Floating Tablet.
2. Multiple Unit type floating pills:
These systems consist of sustained release pills as ‘seeds’ surrounded by 
double layers. The inner 
of swellable membrane layer. When the system is immersed in dissolution medium at 
body temperature it sinks at once and then forms swollen pill like balloon and float as 
the density decreases (Fig. 4&5).
                    Figure No. 4
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3. Multi-unit type oral floating Stages of floating mechanism dosage system                
  A Penetration of water 
  B Generation of CO2 and floating Dissolution of drug 
  C Release of drug from the resorvoir 
II. Volatile Liquid / Vacuum Containing Systems:  
1. Intragastric Floating Gastrointestinal Drug Delivery System: [26] 
This system can be made to float in the stomach because of flotation chamber, 
which may be a vacuum or filled with air or a harmless gas, while drug reservoir is 
encapsulated inside a microporous compartment (Fig. 6).       
 
Figure No. 6: Intra Gastric Floating Gastrointestinal Drug Delivery Device 
2. Inflatable Gastrointestinal Delivery Systems: 
In these systems an inflatable chamber is incorporated, which contains liquid 
that gasifies at body temperature to cause the chamber to inflate in the stomach. These 
systems are fabricated by loading the inflatable chamber with a drug reservoir, which 
can be a drug impregnated polymeric matrix, then encapsulated in a gelatin capsule. 
After oral administration the capsule dissolves to release the drug reservoir together 
with the inflatable chamber. The inflatable chamber automatically inflates and retains 
the drug reservoir compartment in floating position. The drug continuously released 
from the reservoir into the gastric fluid (Fig. 7). 
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                     Figure No. 7: Inflatable Gastrointestinal Delivery System 
3. Intragastric Osmotically Controlled Drug Delivery System: 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach capsule quickly 
disintegrates to release the intragastric osmotically controlled drug delivery device. 
The inflatable support inside forms a deformable hollow polymeric bag that contains a 
liquid that gasifies at body temperature to inflate the bag. The osmotic pressure 
controlled drug delivery device consists of two components; drug reservoir 
compartment and an osmotically active compartment. 
The drug reservoir compartment is enclosed by a pressure responsive 
collapsible bag, which is impermeable to vapour and liquid and has a drug delivery 
orifice. The osmotically active compartment contains an osmotically active salt and is 
enclosed within a semi permeable housing. In the stomach, the water in the GI fluid is 
continuously absorbed through the semi permeable membrane into osmotically active 
compartment to dissolve the osmotically active salt. An osmotic pressure is thus 
created which acts on the collapsible bag and turns in forces the drug reservoir 
compartment to reduce its volume and activate the drug reservoir compartment to 
reduce its volume and activate the drug release in solution form through the delivery 
orifice. 
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The floating support is also made to contain a bioerodible plug that erodes 
after a predetermined time to deflate the support. The deflated drug delivery system is 
then emptied from the stomach (Fig. 8). 
                             
      Figure No. 8: Intragastric Osmotically Controlled Drug Delivery System 
B. Non Effervescent Systems: 
The Non effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
polysaccharides and matrix forming materials such as polycarbonates, polyacrylates, 
polymethacrylates, polystyrenes and bioadhesive polymer such as chitosan and 
carbopol. 
The various types of these systems are: 
1. Single Layer Floating Tablets: [58, 49] 
They are formulated by intimate mixing of drug with a gel-forming 
hydrocolloid, which swells in contact with gastric fluid and maintain bulk density of 
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2.  Alginate Beads: 47 
Multi unit floating dosage forms were developed from freeze-dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by 
dropping a sodium alginate solution into aqueous solution of calcium chloride, 
causing precipitation of calcium alginate leading to formation of porous system, 
which can maintain a floating force for over 12 hours. These floating beads gave a 
prolonged residence time of more than 5.5 hour. 
3.  Hollow Microspheres: 
Multiple-unit hollow microspheres by emulsion solvent diffusion technique 
were prepared with Drug and acrylic polymer. These were dissolved in an ethanol-
dichloromethane mixture, and poured into an aqueous solution of PVA with stirring to 
form emulsion droplets. The rate of drug release in micro balloons was controlled by 
changing the polymer to drug ratio. Micro balloons were floatable in-vitro for 12 
hours when immersed in aqueous media. Radio graphical studies proved that micro 
balloons orally administered to humans were dispersed in the upper part of stomach 
and retained there for 3 hours against peristaltic movements. 
1.4.3 Application of FDDS: [32] 
1. For treating local inflammation and stomach ulcers. 
2. For treating H. Pylori associated ulcers. 
3. In chronic diseases associated with frequent medication and prolonged medication,         
FDDS can be promising drug delivery system. 
1.5 MATRIX SYSTEMS:[13,30,39,55] 
 A matrix is a uniform mixture of drug and excipients. e.g. polymer that is 
homogeneously fixed in solid dosage form. 
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 The drug substance, which has a solubility S gm /cm3 in the dissolution 
medium, is dispersed in the matrix which is insoluble in the dissolution medium, is 
dispersed in the matrix which is insoluble in the dissolution medium. The 
concentration of drug in the matrix is ‘A’ gm / cm3. The matrix is porous, with a 
porosity of ‘Є’ and diffusion coefficient of ‘Dm’. The drug release from such system 
can be described by dQ/dt = 2SDmAt. Liquid will intrude from the bulk liquid. The 
rate and extent of intrusion will follow the following equation: 













 Where, L is the length of the intrusion at time t, r is the average radius of the 







                 Figure No. 9: Dissolution of drug from a solid matrix 
1.5.1. HYDROPHILLIC MATRIX SYSTEM: 
 A hydrophilic matrix controlled release system is a dynamic system composed 
of polymer wetting, polymer hydration and polymer dissolution. At the same time 
other soluble excipients or drug will also wet, dissolve and diffuse out of the matrix 
while insoluble materials will be hold in place until the surrounding polymer/ 
excipients / drug complex erodes or dissolves away. 
 The main principle is that a water-soluble binder, present throughout the 
tablet, partially hydrates on the outer tablet “sink” to form a gel layer. Throughout the 
X = L    X = h  
C = S 
No solid present 
Liquid enters 
C = 0 
X = 0  
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life of ingested tablet the rate of drug diffusion (if soluble) out of the wet gel and the 
rate of tablet erosion control the overall dissolution rate and drug availability. 
 
                             Figure No. 10 :  Matrix System 
.1.5.1.(a). ADVANTAGES OF HYDROPHILIC MATRIX SYSTEM: [21]- 
A hydrophilic matrix system essentially consists of a drug dispersed in a water 
swelling viscous polymer. These systems offer a number of advantages over other 
sustained release technologies namely. 
1. Simplicity of formulation. 
2. High drug loading as high as 80 % is possible in many cases. 
3. The system is usually inexpensive as the rate-controlling agent is usually a                   
GRAS (generally accepted as safe) food polysaccharides. 
4. Number of matrix former is available allowing development of formulations 
that meet special needs and avoid patent infringement. 
5. The systems are eroded as they pass the GIT thus there are no accumulation of 
“Ghosts” or empty shells. 
Chapter  1                                                                                                   Introduction 
Department of Pharmaceutics JKKMMRF College of pharmacy 
 
23
6. As system depends on both diffusion and erosion for drug release, release is 
not totally dependent on GI motility. 
7. No specialized equipment is required which substantially reduces 
manufacturing costs. 
8. Offer easy scalability and process validation due to simple manufacturing 
processes. 
9. The above listed advantages overshadow the undesirable property of reducing 
release rates with time. 
1.5.2. DISADVANTAGES OF HYDROPHILIC MATRIX SYSTEM 
1. Poor patient compliance, increased chances of missing the dose of a drug with 
short half-life for which frequent administration is necessary. 
2. The unavoidable fluctuations of drug concentration may lead to under 
medication or over medication. 
3. A typical peak-valley plasma concentration-time profile is obtained which 
makes attainment of steady-state condition difficult. 
4. The fluctuations in drug levels may lead to precipitation of adverse effects 
especially of a drug with small Therapeutic Index (TI) whenever over 
medication occur. 
1.5.3. MATRIX TYPE: [22] 
The most common controlled delivery system has been the matrix type such as 
tablets and granules, where the drug is uniformly dissolved or dispersed throughout 
the polymer, because of its effectiveness, low cost, ease of manufacturing and 
prolonged delivery time period. 
 Hydrophilic polymers are becoming more popular in formulating oral 
controlled release tablets, it is well documented that the dissolution curve of drug 
release from a hydrophilic matrix shows a typical time dependent profile. The release 
of a dissolved drug inherently follows near first order diffusion either an initially high 
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release rate, due to the dissolution of the drug present at the surface of the matrix 
followed by a rapidly declining drug release rate. The enhanced release rate observed 
at the beginning for the short time of release process is known as “burst effect” and is 
many a time undesirable since it may, have negative therapeutic consequences. After 
this burst effect, hydration and consequent swelling and/or erosion of related polymer 
occur. These phenomenons control the release process but with time, the diffusion 
path length increases and saturation effect is attained, resulting in a progressively 
slow release rate during the end of dissolution span. 
 
               Figure No. 11: Schematic showing the burst effect in a zero-order  
Drug delivery system: 
In many controlled release formulations immediately upon placement in 
release medium, an initial large bolus of drug is release medium; an initial large bolus 
of drug is released before the release rate reaches a stable profile. This phenomenon is 
referred to as burst release. 
 1.5.4. Cause of burst release  
1) Processing conditions  
2) Surface characteristics of host material  
3) Sample geometry  
4) Host and drug interaction (surface adsorption)  
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5) Morphology and porous structure of dry material.  
1.5.5. Prevention of burst release: 
Several advanced technologies to avoid burst include 
a) Surface extraction of active agent  
Approaches have been taken to reduce the initial burst, such as extracting the 
drug formulation for a short period of time in vitro before using them in-vivo 
application. Burst effect is reduced because drug is removed from the outer layers of 
controlled release devices. E.g. Lee showed the effectiveness of surface extraction in 
reducing burst release of Oxprenolol HCl from P-HEMA hydrogen.  
b) Coated surface  
It is another method which prevents burst release is surface modification by 
additional coating steps to provide an outer layer with no drug. Colombo and co-
workers have done extensive work in understanding the influence of exposed surface 
area on drug release. They defined a dimensionless parameter so, the swelling area 





=S .d -------- (2) 
                  Where,  
dA/dt = rate of releasing area charge  
                     D  = drug diffusion coefficient  
c) Drug loading distribution  
Non uniform drug loading, i.e. the increasing concentrations away from 
surface overcome the growing rubbery gel layer. This gel layer typically leads to 
diminishing release rates with time in uniformly loaded gels.  
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d) Polymer morphology and composition 
 The polymer microstructure and hydrophilic/hydrophobic interaction also play 
an important role in determining drug distribution profiles and release characteristics.  
e) Surface modification 
To prevent burst release from porous polymer structures caused by solvent 
evaporation during processing many methods have been attempted which are based 
on changing the surface characteristics of the devices.     
1.6. SWELLING CHARACTERISTICS OF POLYMER: [27] 
The Peppa’s plot is useful to determine whether the drug release from the 
matrix is controlled by swelling of the polymer or not. The Peppa’s equation is                      
log Q = log (kt½) -----------(3) 
              log Q = log k + 0.5 log t ------------(4) 
Where,  
                 Q = amount of drug release in time t per unit area 
                             k = release constant. 
If the slope of a plot of log Q Vs log t is exactly 0.5, then the drug release 
occurs by perfect diffusion obeying Higuchi’s and Fick’s law. If it is in the range of 
0.5 – 1, then the mechanism of release is diffusion and rate of diffusion is controlled 
by swelling of polymer. If it is bellow 0.5, then there is no swelling of matrix occur. 
1.7. MECHANISM OF DRUG RELEASE FROM MATRIX SYSTEM: [46, 21] 
When a hydrophilic matrix system containing a swellable glassy polymer 
comes in contact with an aqueous medium, the fall in glass transition temperature 
leads to an abrupt change from a glassy to a rubbery state, causing swelling of the 
polymer on the surface and formation of a hydrated gel. Drug release is controlled by 
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this gel diffusional barrier and/or by surface erosion of the gel. Surface leaching of 
the drug can lead to an initial burst, especially with highly soluble drugs. 
Hydration of individual polymer chains leads to expansion in their end to end 
distance and radius of gyration to a new solvated state due to lowering of the polymer 
transition temperature, a sharp distinction between glassy and rubbery region is 
observed and the matrix increases in volume because of swelling. 
When the system is hydrated to the core, the drug concentration falls below its 
solubility value and the release rate of the drug begins to decline. A concurrent 
increase in the thickness of the barrier layer with time increases the diffusion path 
length, further reducing the release rate. Drug release kinetic associated with this gel 
layer dynamics, range initially from Fickian to anomalous (Non-Fickian) and 
subsequently from quasi-constant (near zero order) to constant. Matrices of highly 
molecular weight polymers rarely shows all three regimens (Fickian, Non-Fickian and 
quasi-constant) of drug release because of a low chain disentanglement rate and 
insufficient external polymeric mass transfer. 
 Soluble drugs are primarily released by diffusion through aqueous filled 
porous network formed in the inert matrix former due to dissolution and erosion of 
the polymer from the surface. For poorly soluble drugs dispersed in inert polymer 
systems erosion is the primarily release mechanisms. 
There are two major processes that control the drug release from swelling 
controlled matrix systems, these include: 
1. Ingress of aqueous medium into the matrix followed by a hydration, 
gelation or swelling and 
2. Matrix erosion. 
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Simultaneous occurrence of these processes leads to the formation of two 
fronts within the hydrating matrix, this are a swelling front, at the junction of the 
unhydrated glassy matrix and the hydrated matrix and an eroding front where the 
polymer is completely hydrated. Thickness of the diffusion layer, i.e. the distance 
between the two fronts, depends on the relative rates at which the swelling and 
erosion occurs. 
If the polymer gels slowly, solvent can penetrate deep into the glassy matrix, 
thus dissolving the drug; therefore, gel layer thickness and its stability are crucial in 
controlling drug release. Numbers of techniques have been used to study the swelling 
of matrix tablets and to characterize the gel layer and front movement such as, optical 
imaging,1H- NMR, pulsed filled gradient spin echo NMR, confocal laser scanning 
microscopy, cryogenic scanning electron microscopy and texture analysis. The gel 
layer thickness is determined by the relative position of the swelling and erosion front. 
1.8. DRUG RELEASE MECHANISM FROM MATRICES: [29] 
From time to time, various authors have proposed different types of drug 
release mechanisms from matrices. It has been proposed that drug release from the 
matrices usually implies water penetration in the matrix, hydration, swelling, 
diffusion of the dissolved drug (polymer hydro fusion), and / or the erosion of the 
gelatinous layer. However, it is worth mention that the release mechanism of a drug 
would depend on the dosage form selected, pH, and nature of the drug and of course, 
the polymer used.11 
a) Zero order kinetics: 
Drug dissolution from pharmaceutical dosage from that do not disaggregate 
and release the drug slowly (assuming that area does not change and no equilibrium 
conditions are obtained) can be represented by the following equation. 
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W0 –Wt = Kt --------- (5) 
 Where,  
W0 = initial amount of drug in the pharmaceutical dosage form, 
Wt = amount of drug in the pharmaceutical dosage form, 
  t =    time, 
  K = Proportionality constant. 
 The pharmaceutical dosage form following this profile release the same 
amount of drug by unit of time and in this model can be explained by following 
equation: 
Qt = Q0 + K0t ---------------- (6) 
Where,    
   Qt = Drug dissolved in time t,  
               Q0 = Initial amount of drug in solution, 
               K0 = Zero order rate constant. 
    OR, 
                           W = K.t  (Xu and Sunada, 1995) --------- (7) 
Where, 
        W is percentage drug release at time t,  
        K is the release rate constant 
b) First order kinetics: 
The application of this model to drug dissolution studies was first proposed by 
Gibaldi and Feldman (1967) and later by Wagner. The dissolution phenomena implies 






Where,   C = Concentration of solute in time t, 
Chapter  1                                                                                                   Introduction 
Department of Pharmaceutics JKKMMRF College of pharmacy 
 
30
              CS = solubility in equilibrium at experience temperature. 
               k =First order proportionality constant 





 ------------- (9) 
Where, w = amount of solute in solution at time t, 
            S = Solid area accessible to dissolution. 
log Qt = log Q0 + K1.t / 2.303 --------- (10) 
Where,   Qt = amount of drug release in time t,  
              Q0 = initial amount of drug in solution, 
     K1 = First order release constant. 
Above equation also represents this model. 
The pharmaceutical dosage form following this dissolution profile, such as 
those  containing water soluble drugs in porous matrices release drug in a way that is 
proportional to amount of drug remaining in its interior in such a way that amount of 
drug released by unit of time diminish. 
                                             OR,  
       In (100 – W) = In 100 – k t (Singla and Medrata, 1988; and Sunada 1995)-- (11)   
 
1.9. Definition of HIV:  
Human immunodeficiency virus infection / acquired immunodeficiency 
syndrome (HIV/AIDS) is a disease of the human immune system caused by infection 
with human immunodeficiency virus (HIV).[1] During the initial infection, a person 
may experience a brief period of influenza-like illness. This is typically followed by a 
prolonged period without symptoms. As the illness progresses, it interferes more and 
more with the immune system, making the person much more likely to get infections, 
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including opportunistic infections and tumors that do not usually affect people who 
have working immune systems. 
 
HIV is  transmitted  primarily via  unprotected sexual intercourse (including  
anal  and even  oral sex), contaminated blood transfusions, hypodermic needles, 
and from mother to child during pregnancy, delivery, or breastfeeding.[2] Some bodily 
fluids, such as saliva and tears, do not transmit HIV.[3] Prevention of HIV infection, 
primarily through safe sex and needle-exchange programs, is a key strategy to control 
the spread of the disease. There is no cure or vaccine; however, antiretroviral 
treatment can slow the course of the disease and may lead to a near-normal life 
expectancy. While antiretroviral treatment reduces the risk of death and complications 
from the disease, these medications are expensive and may be associated with side 
effects. 
Acquired immunodeficiency syndrome (AIDS) is defined in terms of either a 
CD4+ T cell count below 200 cells per µL or the occurrence of specific diseases in 
association with an HIV infection. In the absence of specific treatment, around half of 
people infected with HIV develop AIDS within ten years. The most common initial 
conditions that alert to the presence of AIDS are pneumocystis 
pneumonia (40%),cachexia in the form of HIV wasting syndrome (20%) 
and esophageal candidiasis. Other common signs include recurring respiratory tract 
infections.  
Opportunistic infections may be caused by bacteria, viruses, fungi and parasites that 
are normally controlled by the immune system. Which infections occur partly depends 
on what organisms are common in the person's environment. These infections may 
affect nearly every organ system.  
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People with AIDS have an increased risk of developing various viral induced 
cancers including Kaposi's sarcoma, Burkitt's lymphoma, primary central nervous 
system lymphoma, and cervical cancer. Kaposi's sarcoma is the most common cancer 
occurring in 10 to 20% of people with HIV. The second most common cancer is 
lymphoma which is the cause of death of nearly 16% of people with AIDS and is the 
initial sign of AIDS in 3 to 4%. Both these cancers are associated with human herpes 
virus. Cervical cancer occurs more frequently in those with AIDS due to its 
association with human papillomavirus (HPV).  
Additionally, people with AIDS frequently have systemic symptoms such as 
prolonged fevers, sweats (particularly at night), swollen lymph nodes, chills, 
weakness, and weight loss. Diarrhea is another common symptom present in about 
90% of people with AIDS. They can also be affected by diverse psychiatric and 
neurological symptoms independent of opportunistic infections and cancers 
Classification of Anti Viral drugs: 
Agents to treat Herpes Simplex Virus (HSV) & Varicella Zoseter Virus (VZV) 
infections 
 Acyclovir, Valcyclovir, Famciclovir, Penciclovir, Trifluridine.  
Agents to treat Cytomegalovirus (CMV) infections 
 Ganciclovir, Valganciclovir, Cidofovir, Foscarnet, Fomivirsen. 
Antiretroviralagents:  
Nucloside Reverse Transcriptase Inhibitors (NRTIs) 
 Zidovudine, Didanosine, Lamivudine, Zalcitabine, Stavudine, Abacavir. 
Antiretroviralagents:  
Nucleutide inhibitors 
 Tenofovir  
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Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
 Nevirapine, Delaviridine, Efavirenz. 
Antiretroviralagents:  
Protease Inhibitors 
 Saquinavir, Ritonavir, Lopinavir, Indinavir, Nelfinavir, Ampernavir.   
Fusion Inhibitors 
 Enfuvirtide (HIV), Docosanol (HSV). 
Anti-Hepatitis agents 
 Lamivudine, Ribavirin, Pegylated interferon alpha, Interferon alpha, Adefovir. 
Anti-Influenza Agents 
 Amantadine, Rimantadine, Zanamivir, Oseltamivir. 
Other Antiviral agents 
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                   The major sites of antiviral drug action 
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2. LITERATURE REVIEW 
 Syed Ershad et al., (2013) prepared Floating microspheres of Ritonavir by ionic 
gelation method with an aim of increasing the gastric residence time and for 
controlled release. Sodium alginate, polymeric mixture of Sodium alginate and 
xantham gum were used as polymers. Sodium bicarbonate was used as the gas-
forming gent. The prepared floating microspheres were evaluated with respect to 
particle size distribution, floating behavior, drug content, entrapment efficiency, 
morphology and in vitro release study. These results indicated that the release rate 
was found to decrease with increase in concentration of coating material applied. The 
wall thickness of microspheres was found to be increased with the increase in 
concentration of coating material applied. The floating microspheres followed zero 
order kinetics and the mechanism of drug release was governed by peppas model.  
 
 K.P.R Chowdhary et al., (2011) prepared, characterized and evaluated starch 
phosphate, a new modified starch as a carrier in solid dispersions for enhancing the 
dissolution rate of ritonavir. The feasibility of formulating solid dispersions of 
ritonavir in starch phosphate into compressed tablets with enhanced dissolution rate 
was also investigated. Starch phosphate was prepared by reacting starch with di-
sodium hydrogen orthophosphate anhydrous at elevated temperatures. It was insoluble 
in water and has good swelling (400%) property without pasting or gelling when 
heated in water. Solid dispersions of ritonavir in starch phosphate were prepared by 
solvent evaporation method employing various weight ratios of drug: starch 
phosphate such as 2:1(SD-1), 1:1(SD-2), 1:2(SD-3), 1:3(SD-4) and 1:9(SD-5) and 
were evaluated for dissolution rate and efficiency. All the solid dispersions prepared 
gave rapid and higher dissolution of ritonavir when compared to pure drug. A 58.34 
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and 94.41 fold increase in the dissolution rate (K1) of ritonavir was observed with 
solid dispersions SD-4 and SD-5 respectively. The DE30 was also increased from 
6.80% in the case of ritonavir pure drug to 76.25% and 84.05% in the case of these 
solid dispersions. Ritonavir (50 mg) tablets were prepared employing ritonavir alone 
and its solid dispersions SD-3 and SD-4 by wet granulation method and were 
evaluated. Ritonavir tablets formulated employing its solid dispersions in starch 
phosphate gave rapid and higher dissolution rate and DE30 when compared to plain 
and commercial tablets. A 9.95 and 28.14 fold increase in the dissolution rate (K1) 
was observed with tablet formulations containing solid dispersions SD-3 and SD-4 
respectively when compared to plain tablets. 
 
M.S. Hasoliya et al., (2012) prepared Floating microspheres of Ritonavir by simple 
dripping method with an aim of increasing the gastric residence time and for 
controlled release. A polymeric mixture of Sodium alginate and hydroxy propyl 
methyl cellulose was used. Sodium bicarbonate was used as the gas-forming gent. The 
solution was dropped to 1% calcium chloride solution containing 10 % acetic acid for 
carbon dioxide release and gel formation. The prepared floating microspheres were 
evaluated with respect to particle size distribution, floating behavior, drug content, 
entrapped, morphology and in-vitro release study. Effect of sodium bicarbonate on the 
above mentioned parameters were evaluated and it was found that the sodium 
bicarbonate had a pronounced effect on various parameters. The enhanced buoyancy 
and controlled release properties of sodium bicarbonate containing microspheres 
made them an excellent candidate for floating dosage form.  
 Kanagala Vijayasri et a l., (2013) prepared and evaluated montmorillonite (natural 
clay material) for enhancing the dissolution rate of drug by formulating solid 
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dispersions of ritonavir in montmorillonite into compressed tablets. Solid dispersions 
of ritonavir in montmorillonite were prepared by solvent evaporation method 
employing various weight ratios of drug: montmorillonite such as 1:1(SD-1), 1:2(SD-
2), 1:4(SD-3) and 1:7 (SD-4). The tablets were evaluated. Prior to compression, the 
pre-compression parameters showed satisfactory flow properties. Post-compression 
parameters showed that all tablet formulations had acceptable mechanical properties. 
The compatibility of the drug in the formulation was confirmed by IR and DSC 
studies. Ritonavir tablets formulated employing its solid dispersion in montmorillonite 
gave rapid and higher dissolution rate and DE30 when compared to plain tablets. A 
14, 12 and 8 fold increase in the dissolution rate (k1) was observed with tablet 
formulations containing solid dispersions SD-1, SD-2 and SD-3 respectively when 
compared to plain tablets 
K.P.R. Chowdhary et al., (2012) comparatively evaluated three commercially 
available DCVs namely Lubritose AN, Lubritose SD, Lubritose MCC and one 
laboratory made DCV namely starch phosphate, a new modified starch in the 
formulation development of three antiretroviral drugs by direct compression method. 
Tablets of (i) Efavirenz (100 mg) (ii) Ritonavir (100 mg) and (iii) Stavudine (30 mg) 
were formulated employing the four directly compressible vehicles and the tablets 
were evaluated for various physical properties and dissolution rate. All the tablets 
gave rapid dissolution of the contained drug. The dissolution was complete (100%) 
within 15 – 30 min with all the drugs and the dissolution was much higher than the 
official requirement in each case. Stavudine tablets exhibited faster dissolution than 
those of efavirenz and ritonavir with all the four DCVs. Hence these DCVs are 
recommended for the preparation of tablets of antiretroviral drugs by direct 
compression method. 
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Rabhi Narayan parhi et al., (2013) developed a floating drug delivery system of 
ritonavir (RN) in order to prolong the gastric residence time and increase its 
bioavailability. The floating tablets of RN were prepared by direct compression 
technique, using polymers such as different grades of hydroxypropyl methylcellulose 
(HPMC, Methocel E15LV, E50LV, K100LV and K4M) and polyvinyl pyrrolidone 
(PVP K30). Sodium bicarbonate was used as gas releasing agent. The formulations 
were optimized on the basis of matrix integrity, duration of floating, swelling 
behavior and in vitro drug release. Except series FA, where floating time was 10 hr, 
other series such as FB, FC and FD were showing more than 12 hr of floating time. 
The mechanism of RN release from the floating tablets for FA, FB and FC series is 
anomalous diffusion transport and follows zero order kinetics, but FD series indicated 
Higuchi kinetics with release rate exponent (n) of 0.44. Further, the scanning electron 
microscopy showed porous structured formed on the tablet surface at different times 
(0, 3, 6, 9 and 12 hr) of dissolution for the selected batch FC3. Finally, FC3 batch 
showed no significant change in above parameters after storage at room temperature 
(28-32°C), 40°C and 50°C for one month. 
Raju B et al., (2012) studied and developed ritonavir is an antiretroviral drug with 
activity against Human Immunodeficiency Virus (HIV) type 1.  In the present work 
an attempt is being made to provide for parenteral drug delivery with having 
improved therapeutic index for Ritonavir and anintention to develop a stable and 
effective parenteral formulation, containing the drug Ritonavir. Ritonavir is 
practically insoluble in water and unstable at higher temperature. The effects of 
various co solvents in the solubility of Ritonavir have been evaluated. Ritonavir was 
tried with co solvents such as Sodium-p-hydroxy benzoate, Sodium glycinate and 
Sodium thiocyanate. The drug was made into injection formulation for administered 
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as a SVP. Various batches of Ritonavir injection formulation were prepared in order 
to assess the influence of heat, light, atmospheric oxygen and antioxidant on the 
stability of the drug and the formulations were also subjected to accelerated stability 
test. Out of all trials, formulation containing Sodium thiocyanate was found to be 
more soluble, stable and passed all tests satisfactorily. 
Chandira Margret R et al., (2010) developed floating tablets of Itopride hydro 
chloride, a novel pro kinetic drug, which after oral administration are designed to 
prolong the gastric residence time and thereby increase drug bioavailability and drug 
release rate. This would help in promoting gastro intestinal transit and speed up 
gastric motility and thereby it will relieve the symptoms associated with it. Floating 
tablets were fabricated using direct compression method containing itopride 
hydrochloride, polymers HPMC K100M, HPMC K15M and carbopol 934P along 
with gas generating agent sodium bicarbonate and citric acid. The addition of 
carbopol aided in the reduction of drug dissolution due to their hydrophobic nature. 
The concentration of these agents was also optimized to get desired controlled release 
of drug. The floating tablet formulations were evaluated for physical characterization, 
assay, swelling index, in-vitro drug release, hardness, friability and weight variation. 
The results indicated that gas powered floating tablets of Itopride hydrochloride 
containing 125mg HPMC K 100M, 40 mg HPMC K 15M and 40 mg  carbopol 
provides a better option for 24 hrs release action and improved bioavailability 
mechanism.  
Margret Chandira et al., (2009) Prepared Diltiazem Hydrochloride undergoes an 
extensive biotransformation, mainly through cytochrome P-450 CYP3A, which 
results in less than 4% of its oral dose being excreted unchanged in urine. Suffers 
from poor bioavailability (~30% to 40%) owing to an important first pass metabolism. 
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It has an elimination half-life of 3.5 hrs and an absorption zone from the upper 
intestinal tract. Thus the present work is aimed to formulate floating tablets of 
Diltiazem Hydrochloride using an effervescent approach for gastro retentive drug 
delivery system. Floating tablets were prepared using direct compression technique 
using Hydrophilic polymer like HPMC K4M, HPMC K15M and hydrophobic 
polymer like Ethyl cellulose as matrix materials in various quantities (%w/w), sodium 
bicarbonate, citric acid, magnesium stearate, talc and lactose in varying ratio to 
formulate the floating tablets. Observations of all formulations for physical 
characterization had shown that, all of them comply with the specification of official 
pharmacopoeias and/or standard reference. It was observed that tablets of batch F6 
followed the results obtained, it was concluded that the formulation F6 is the best 
formulations as the extent of drug release was found to be around 99.81 % at the 
desired time 12 hrs. 
Desai.S et al., (1993) studied A novel floating controlled-release drug delivery  was 
formulated in an effort increase the gastric retention time of the dosage form and to 
control drug release. The buoyancy was attributed to air and oil entrapped in the agar 
gel network. A floating controlled-release 300mg theophylline tablet having a density 
of 0.67 was prepared and compared in-vitro and in vivo to Theo-dur. The in-vitro 
release rate of the floating tablet was slower. In-vivo scintigraphic studies for a 
floating and a heavy nonfloating tablet, under fasting and nonfasting conditions, 
showed that the presence of food significantly increased the gastric retention time for 
both tablets, and tablet density did not appear to make a difference in the gastric 
retention time. However, the positions of the floating and nonfloating tablets in the 
stomach were very different. Bioavailability studies in human volunteers under both 
fasting and nonfasting conditions showed results comparable to those with Theo-dur. 
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The floating controlled-release theophylline tablet maintained constant theophylline 
levels of about 2 mg/mL for 24 hr, which may be attributable to the release from the 
agar gel matrix and the buoyancy of the tablet in the stomach. 
Ravi Kumar et al., (2009) development and evaluation of floating tablets of 
famotidine which, after oral administration, are designed to prolong the gastric 
residence time, increase drug bioavailability and target the gastric ulcer. A floating 
drug delivery system (FDDS) was developed using gas-forming agents, like sodium 
bicarbonate, citric acid and hydrocolloids, like hydroxypropyl methylcellulose 
(HPMC) and carbopol 934P. The formulations were optimized for the different 
viscosity grades of HPMC, carbopol 934P and its concentrations and combinations. 
The results of the in-vitro release studies showed that the optimized formulation (F12) 
could sustain drug release (98%) for 24 h and remain buoyant for 24 h. The optimized 
formulation was subjected to various kinetic release investigations and it was found 
that the mechanism of drug release was predominantly diffusion with a minor 
contribution from polymeric relaxation. Optimized formulation (F12) showed no 
significant change in physical appearance, drug content, total buoyancy time or in 
vitro dissolution study after storage at 45 °C/75% RH for three months. Finally the 
tablet formulations found to be economical and may overcome the draw backs 
associated with the drug during its absorption. 
Shishu, Gupta N, Aggarwal N et al., (2007)   developed and evaluated the single 
unit floating tablets of 5-FU which, after oral administration, are designed to prolong 
the gastric residence time, increase drug bioavailability and target the stomach cancer. 
Methods: A floating drug delivery system (FDDS) was developed using gas-forming 
agents, like sodium bicarbonate, citric acid and hydrocolloids, like hydroxypropyl 
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methylcellulose (HPMC) and Carbopol 934P. The prepared tablets were evaluated in 
terms of their physical characteristics, in vitro release, buoyancy, buoyancy lag-time 
and swelling index. The formulations were optimized for the type of filler, like 
lactose, microcrystalline cellulose (MCC) and dicalcium phosphate (DCP) as well; 
different viscosity grades of HPMC and concentrations. Results: The results of the in-
vitro release studies showed that the optimized formulation could sustain drug release 
for 24 h and remain buoyant for 16 h. When these dissolution profiles were subjected 
to various kinetic release investigations and it was found that the mechanism of drug 
release was predominantly diffusion with a minor contribution from polymeric 
relaxation.  
R Garg et al., (2008) studied that Controlled release (CR) dosage forms have been 
extensively used to improve therapy with several important drugs. However, the 
development processes are faced with several physiological difficulties such as the 
inability to restrain and localize the system within the desired region of the 
gastrointestinal tract and the highly variable nature of the gastric emptying process. 
This variability may lead to unpredictable bioavailability and times to achieve peak 
plasma levels. On the other hand, incorporation of the drug in a controlled release 
gastro retentive dosage forms (CR-GRDF) which can remain in the gastric region for 
several hours would significantly prolong the gastric residence time of drugs and 
improve bioavailability, reduce drug waste, and enhance the solubility of drugs that 
are less soluble in high pH environment. Gastro retention would also facilitate local 
drug delivery to the stomach and proximal small intestine. Thus, gastro retention 
could help to provide greater availability of new products and consequently improved 
therapeutic activity and substantial benefits to patients. Controlled gastric retention of 
solid dosage form may be achieved by the mechanisms of floatation, mucoadhesion, 
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sedimentation, expansion or by a modified shaped system. The purpose of this paper 
is to review the recent literature and current technology used in the development of 
gastro retentive dosage forms. 
Patel Geeta M et al., (2007) studied Oral delivery of the drug is by far the most 
preferable route of drug delivery due to the ease of administration, patient compliance 
and flexibility in the formulations. From immediate release to site-specific delivery, 
oral dosage form has really progressed. It is evident from the recent scientific and 
patented literature that an increased interest in novel dosage forms that are retained in 
the stomach for the prolong and predictable period of time exist today in academic 
and industrial research groups. Various attempts have been made to develop Gastro 
retentive delivery systems.  
Abdul Sayeed et al., (2011) development of controlled release oral drug delivery 
systems by overcoming physiological adversities like short gastric residence times 
and unpredictable gastric emptying times. Floating tablets are the systems which are 
retained in the stomach for a longer period of time and there by improve the 
bioavailability of drugs. Floating tablets were prepared using directly compression 
technique using polymers like HPMC K4M HPMC K15M and HPMCK100M for 
their gel forming properties.  
Peterson Bhoi et al., (2010) developed floating matrix drug delivery system of 
Diclofenac sodium to prolong gastric residence time and increase its bioavailability. 
Floating matrix tablets containing 100 mg Diclofenac sodium were developed using 
different bees wax combinations. The tablets were prepared by melt granulation 
technique, using polymers such as Hydroxy propyl methyl cellulose (HPMC K15M), 
ethyl cellulose, bees wax alone or in combination with Cetyl alcohol and other 
Chapter2 Literature Review 
Department of Pharmaceutics JKKMMRF College of pharmacy 
 
44
standard excipients. Sodium bicarbonate was incorporated as a gas-generating agent. 
The effects of sodium bicarbonate on floating properties were investigated. The 
formulation was optimized on the basis of acceptable tablet properties, floating lag 
time, and total duration of floating and in vitro drug release. The resulting formulation 
produced monolithic tablets with optimum hardness, uniform thickness, consistent 
weight uniformity and low friability. The results of dissolution studies, floating lag 
time indicates that formulations F6 exhibited good and controlled drug release. 
Applying the linear regression analysis and model fitting, the selected formulation F6 
showed diffusion coupled with erosion drug release mechanism, followed first order 
kinetics.  
Patel DM et al., (2011) describes an influence of ratio of Gelucire 
43/01(hydrophobic) to hydroxypropyl methylcellulose K4M (HPMC K4M) 
(hydrophilic) and different fillers on release of famotidine from gastro-retentive 
tablets using 3(2) full factorial design. Ratio of Gelucire 43/01 to HPMC K4M (X(1)) 
and the type of filler (X(2)) were selected as independent variables while buoyancy 
lag time (BLT), drug release at 1h (Q(1)), 6h (Q(6)), and the 12h (Q(12)) were 
selected as dependent variables. Gastro-retentive tablets of famotidine were prepared 
by a solvent free melt granulation technique using Gelucire 43/01 as a hydrophobic 
meltable binder. HPMC K4M and sodium bicarbonate were used as matrixing agent 
and gas-generating agent, respectively. Prepared tablets were evaluated for in-vitro 
dissolution, in-vitro buoyancy, friability, hardness, and drug content and weight 
variation. Dissolution data were fitted to various models to ascertain kinetics of drug 
release. The data were analyzed using regression analysis and analysis of variance. 
All formulations (F (1)-F (9)) showed floating within 3min and had total floating time 
of more than 12h. It was observed that a type of filler and the ratio of Gelucire 43/01 
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to HPMC K4M had significant influence on buoyancy lag time (P = 0.037) and Q (6) 
(P = 0.011), respectively without significant influence on Q (1) and Q 
(12).Formulation F (5) was selected as an optimum formulation as it showed more 
similarity in dissolution profile with theoretical profile (Similarity factor, f (2) = 
83.01). The dissolution of batch F (5) can be described by zero order kinetics (r (2) = 
0.9914) with anomalous (non-Fickian) diffusion as a release mechanism (n = 0.559). 
The difference observed in in-vitro release profile after temperature sensitivity study 
at 40°C for 1 month was insignificant. 
Manoj N. Gambhire et al (2007) developed a floating drug delivery system of 
diltiazem hydrochloride (DTZ) to prolong gastric residence time and increase its 
bioavailability. Rapid gastrointestinal transit could result in incomplete drug release 
from the drug delivery system above the absorption zone leading to diminished 
efficacy of the administered dose. The tablets were prepared by direct compression 
technique, using polymers such as hydroxypropylmethylcellulose (HPMC, Methocel 
K100M CR), Compritol 888 ATO, alone or in combination and other standard 
excipients. Sodium bicarbonate was incorporated as a gas-generating agent. The 
effects of sodium bicarbonate and succinic acid on drug release profile and floating 
properties were investigated. A 32 factorial design was applied to systematically 
optimize the drug release profile. The amounts of Methocel K100M CR (X1) and 
Compritol 888 ATO (X2) were selected as independent variables. The time required 
for 50% (t50) and 85% (t85) drug dissolution were selected as dependent variables. The 
results of factorial design indicated that a high level of both Methocel K100M CR 
(X1) and Compritol 888 ATO (X2) favors the preparation of floating controlled release 
of DTZ tablets. Comparable release profiles between the commercial product and the 
designed system were obtained. The linear regression analysis and model fitting 
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showed that all these formulations followed Korsmeyer and Peppas model, which had 
a higher value of correlation coefficient (r). While tablet hardness had little or no 
effect on the release kinetics and was found to be a determining factor with regards to 
the buoyancy of the tablets. 
MD. Tabasum et al., (2013) aimed to work on preparation and evaluation of 
diclofenac sodium controlled release matrix tablets using various proportions of 
natural polymer Abelmoschusesculentus mucilage powder (i.e; Drug: Polymer ratio-
1:0.25,1:0.5,1:1,1:1.5,1:2) as release controlling factor by Wet Granulation method. 
The tablets were evaluated for various parameters like friability, weight variation, 
hardness, drug time, content uniformity. In vitro drug release characteristics of dosage 
form was evaluated in 6.8 pH phosphate buffer. All the formulations followed zero 
order kinetics along with diffusion mechanisms. From In vitro release data, 
formulation F4 containing Drug: Polymer (1:1.5) showed maximum drug release of 
99.8%. All the formulations F1 to F5 undergo Non-Fickian diffusion or Enomalous 
diffusion mechanism. Analysis of drug release rate from matrix system indicated drug 
was release by super case-II transport mechanism. 
G. Rajalakshmi et al., (2011) prepared oral effervescent tablets of diclofenac 
potassium. Six different formulations were prepared using different diluents, 
carbonates by wet granulation and direct compression method. The prepared tablets 
were evaluated for various pre compression characteristics (like angle of repose, bulk 
density, tapped density, cars index and hausner’s ratio) and post compression 
characteristics (like weight variation, hardness friability ,drug content, disintegration, 
CO2 content, effervescent time, particle size and in vitro dissolution studies). The 
dissolution test was carried out in SIF without enzymes, 0.1N HCl and pH 4.8 acetate 
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buffers. Among all the formulations, its F3 formulations were better in all the terms of 
precompression and post compression parameters. In F3 formulations, F3A (by direct 
compression) and F3B (by wet granulation method) were there. F3B (composed of 
active dextrates (Emdex), citricacid, tartaric acid, effersoda and arginine) had given 
good pre formulation and post compression studies as F3A. Even the drug release in 
the medium SIF pH6.8 without enzymes was 99.2% when compared to F3A (98.7%) 
and marketed tablet (98%).It had all the qualities of a good effervescent tablet, based 
on this F3B formulation was selected as the best formulation, and it was charged for 
stability studies. It had given better release profile in all the mediums when compared 
to marketed conventional tablet (SUPANAC). A better therapeutic objective can be 
obtained by formulating effervescent tablet of diclofenac potassium that may help in 
obviating the demerits of slow release and slow absorption, gastrointestinal side 
effects of normal tablets  
Chandrasekhara rao Barru et al., (2012) prepared Ibuprofen by Direct compression 
method, 4 formulations (F1 to F4) floating tablets of Ibuprofen were prepared using 
variable concentrations of HPMCE5M and Carbopol940,buoyancy lag time and the 
total floating time was studied for all the formulations, The compatibility evaluations 
were performed by DSC analysis. Studies imply that polymers are compatible with 
each other. There was no interaction found between polymer and drug. The research 
was undertaken with the aim to formulate and characterize the sustained release 
floating tablets of Ibuprofen using HPMCK4M and Carbopol 940 as polymers. 
Kurnal et al., (2011) prepared a gastro retentive drug delivery system of 
Mebendazole. Chitosan and hydroxypropyl methyl cellulose of various viscosity were 
used. Sodium bicarbonate was incorporated as a gas‐generating agent. The effects of 
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citric acid and stearic acid on drug release profile and floating properties were 
investigated. The addition of stearic acid reduces the drug dissolution due to its 
hydrophobic nature. The specific s tudy was carried out to formulate such a dosage 
form that can neutralize the acidity locally in the stomach. The granulation was 
formed by Fluidized bed processor in which top spray technique was adopted for 
forming the granules. 
Patel UK et al., (2008) developed amlodipine besylate effervescent floating tablets in 
ten different formulations (F1 to F10) by employing different grades of polymers and 
effervescent agents such as sodium bicarbonate and citric acid. The formulations were 
evaluated for various physical parameters, buoyancy studies, dissolution parameters 
and drug released mechanisms. F10 formulation showed maximum floating time of 24 
hours and gave slow and maximum drug release of Amlodipine besylate spread over 
24 hours and whereas Amlodipine besylate released from marketed tablet was rapid 
and maximum within 12 hours. 
Rupavath Mahendar et al., (2012) developed Gastro retentive floating matrix tablets 
to increase the gastric residence time of the drug after oral administration, at a 
particular site and controlling the release of drug especially useful for achieving 
controlled plasma concentration and improving bioavailability. With the above 
objective, floating tablets containing Stavudine without the gas generating agent was 
designed for the treatment of HIV and AIDS. The matrix tablets were prepared by 
using natural polymer such as pullulan gum. The drug release kinetics study reveals 
that the formulations follow first order release with diffusion mechanism. In vivo x-
ray studies showed the gastric residence time of the tablet up to 8 hours. The release 
and floating was depends on the polymer proportion in the matrix tablets. The 
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formulations were evaluated for in vivo floating time which shows the floating time 
up to 12 hours. The DSC and FTIR study shows that there is no drug polymer 
interaction. 
CH.Swarna kamala et al., (2012  formulated and evaluated gastro retentive floating 
drug delivery system containing gabapentin in the form of tablets using polymers like 
HPMC K100M, HPMC K15M, Polyox WSR 303 and sodium bicarbonate as gas 
generating agent. The tablets were prepared by direct compression method. The 
tablets were evaluated for the pre and post compression parameters such as weight 
variation, thickness, friability, hardness, drug content, in vitro buoyancy studies, and 
in vitro dissolution studies and results were within the limits. The in-vitro dissolution 
studies were carried out in a USP type-II apparatus in 0.1 N HCl. Among all the 
formulations (F1 to F9) prepared, batch F7 was the best formulation which showed 
buoyancy lag time 6sec and the tablet remained buoyant for > 24h. At all the strengths 
of the polymer tested combination of HPMC K100M and POLYOX WSR 303 (2:1) 
gave relatively slow release of gabapentin over24 h when compared to other 
formulations. The in-vitro data is fitted in to different kinetic models and the best-fit 
was achieved with the Higuchi model. The optimized formulation F7 followed first 
order release kinetics followed by non fickian diffusion. 
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3. AIM AND PLAN OF WORK 
Aim: 
   The present research work was to develop a floating drug delivery 
system of ritonavir (RN) in order to prolong the gastric residence time and increase its 
bioavailability. Ritonavir  is moderately weekly acidic drug, the stomach is the major 
absorption site for the drug. So by increasing the GRT of the drug, the bioavailability 
can be increased 
  The formulation may remained in the stomach and / or upper part of GIT for 
prolonged period of time thereby giving sufficient time for drug candidate to achieve 
maximum bioavailability(Moumita Biswas2013), and reduce unwanted side effects 
by minimizing or avoiding drug release at unfavorable site. 
Objective: 
The objective of the present work is to formulate and evaluate oral floating 
matrix tablets of  Ritonavir 100mg, using hydrophillic polymers such as HPMC K4M, 
K15M and K100M of 100,150 and 200mg, by taking the single polymer in each 
formulation using Sodium bicarbonate as gas generating agent by direct compression 
technique  to sustain the release of drug due to floating in stomach  at acidic pH 1.2 
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3.1. PLAN OF WORK 
1.  Literature survey 
2.  Preformulation studies 
• Selection of drug. 
• Compatibility study using Fourier Transform Infrared Spectrophotometer. 
• Analytical characterization of the drug. 
• Selection of the excipients. 
• Characterization of the excipients. 
3. Standard calibration curve of drug 
 
4. Formulation development 
• Formulation of the floating tablet by Direct compression technique 
• Effect of the formulation variables on the drug release, swelling and floating 
properties. 
4. Evaluation of tablets 
• Tablet characteristics. 
1) Weight variation 
2) Friability 
3) Hardness 
4) Drug content 
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• In-vitro Buoyancy study. 
• Water uptake studies.  
• In-vitro drug release studies of tablets. 
5. Study of drug release kinetics. 
6. Stability study of the optimized  
 
         FLOW CHART OF WORK 
Selection of drug 
Compatibility study between drug and polymers 
Analytical characterization of the drug by determining characterization of drug 
Selection of excipients 
Characterization of the excipients 
Preformulation studies 
Preparation of ritonavir floating tablets by direct compression technique 
Evaluation of floating tablets 
Drug release kinetics 
Stability studies of optimized formulation 
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4. MATERIALS AND METHODS 
 Materials: 
Table No.4: List of Chemicals Used 
SR.NO. NAME OF THE CHEMICAL SUPPLIER 
1.  RITONAVIR YARROW CHEMICALS , 
MUMBAI 
2.  HYDROXY  PROPYL METHYL 
CELLULOSE K4M,K15M,K100M 
YARROW CHEM PRODUCTS 
MUMBAI, INDIA. 
3.  MICROCRYSTALLINE 
CELLULOSE 
THOMAS BAKER Pvt Ltd, 
MUMBAI. 
4.  SODIUM BICARBONATE THOMAS BAKER Pvt Ltd, 
MUMBAI. 
5.  POLYVINYL PYRROLIDONE 
K30 
SD FINE CHEMICALS 
6.  MAGNESIUM STEARATE THOMAS BAKER Pvt Ltd, 
MUMBAI. 
7.  TALC THOMAS BAKER Pvt Ltd, 
MUMBAI. 
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 Equipments: 
 Table No.5: List of Instruments Used 
Instrument Used Model No. Make 
FTIR Spectrophotometer 8400S Shimadzu, Japan 
UV–Visible 
Spectrophotometer 
UV – 3000+ LAB INDIA 
Tablet Compression Machine Mini Press Rimek 
Tablet Dissolution Tester 
USP (XXIII) 
DS-8000 LAB INDIA 
Environmental test chamber JRIC – 11A Oswald 
Electronic Balance AGN-303EC AXIS 
Tablet hardness tester N.S Monsanto 
Roche's friabilator N.S Scientific 
Hot air oven PYROCON York Scientific Ind., 
Mumbai 
Digital pH meter PHAN LAB INDIA 




Chapter 4   Materials and Methods 
Department of Pharmaceutics                 JKKMMRF College of Pharmacy 55
4.1 DRUG PROFILE 
RITONAVIR 
NORVIR (ritonavir) is an inhibitor of HIV-1 protease with activity against the 
Human Immunodeficiency Virus (HIV) type 1. 
 
Structure of Ritonavir: 
 
Molecular formula:  
 C37H48N6O5S2 
 Relative Molecular Mass: 
 720.95 





 Ritonavir is a white to light tan powder. 
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It is odourless. 
It having a bitter metallic taste 
 Physical Properties of Ritonavir:  
Physical State:    Solid  
Solubility:       It is freely soluble in methanol and ethanol, soluble in isopropanol and 
practically insoluble in water.  
Storage:          Store at room temperature 
Half Life:    3-5hrs 
CLINICAL PHARMACOLOGY 
Pharmacokinetics: 
The pharmacokinetics of ritonavir have been studied in healthy volunteers and 
HIV-1 infected patients (CD4 greater than or equal to 50 cells per µL). See Table 6 
for ritonavir pharmacokinetic characteristics. 
Absorption: 
The absolute bioavailability of ritonavir has not been determined. 
Effect of Food on Oral Absorption: 
After a single 600 mg dose under non-fasting conditions, in two separate studies, the 
soft gelatin capsule (n = 57) formulation yielded a mean ± SD area under the plasma 
concentration-time curve (AUC) of 121.7 ± 53.8. Relative to fasting conditions, the 
extent of absorption of ritonavir from the soft gelatin capsule formulation was 13% 
higher when administered with a meal (615 KCal; 14.5% fat, 9% protein, and 76% 
carbohydrate). 
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Metabolism: 
Nearly the entire plasma radioactivity after a single oral 600 mg dose of 14C-ritonavir 
oral solution (n = 5) was attributed to unchanged ritonavir. Five ritonavir metabolites 
have been identified in human urine and feces. The isopropylthiazole oxidation 
metabolite (M-2) is the major metabolite and has antiviral activity similar to that of 
parent drug; however, the concentrations of this metabolite in plasma are low. In 
vitro studies utilizing human liver microsomes have demonstrated that cytochrome 
P450 3A (CYP3A) is the major isoform involved in ritonavir metabolism, although 
CYP2D6 also contributes to the formation of M-2. 
Elimination: 
In a study of five subjects receiving a 600 mg dose of 14C-ritonavir oral 
solution, 11.3 ± 2.8% of the dose was excreted into the urine, with 3.5 ± 1.8% of the 
dose excreted as unchanged parent drug. In that study, 86.4 ± 2.9% of the dose was 
excreted in the feces with 33.8 ± 10.8% of the dose excreted as unchanged parent 
drug. Upon multiple dosing, ritonavir accumulation is less than predicted from a 






Chapter 4   Materials and Methods 
Department of Pharmaceutics                 JKKMMRF College of Pharmacy 58
Table 6: Pharmaco kinetic parameters of Ritronavir 
PK Parameter Normal Healthy adults20 to 50 years 
 Mean Coefficient of Variation (%) 
Vß/F 91 0.41 ± 0.25 L/kg 
t½  3-5hrs 
Oral Clearance (CL/Fss; mL/min) [N = 61] 10 8.8 ± 3.2 L/h 
CL/F 91 4.6 ± 1.6 L/h 
CLR 62 < 0.1 L/h 
RBC/Plasma Ratio  0.14 
Percent bound  98-99% 
Effects on Electrocardiogram 
QTcF interval was evaluated in a randomized, placebo and active 
(moxifloxacin 400 mg once-daily) controlled crossover study in 45 healthy adults, 
with 10 measurements over 12 hours on Day 3. The maximum mean (95% upper 
confidence bound) time-matched difference in QTcF from placebo after baseline 
correction was 5.5 (7.6) milliseconds (msec) for 400 mg twice-daily ritonavir. 
Ritonavir 400 mg twice daily resulted in Day 3 ritonavir exposure that was 
approximately 1.5 fold higher than observed with ritonavir 600 mg twice-daily dose at 
steady state. 
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PR interval prolongation was also noted in subjects receiving ritonavir in the 
same study on Day 3. The maximum mean (95% confidence interval) difference from 




Gender, Race and Age: 
No age-related pharmacokinetic differences have been observed in adult 
patients (18 to 63 years). Ritonavir pharmacokinetics have not been studied in older 
patients. 
A study of ritonavir pharmacokinetics in healthy males and females showed 
no statistically significant differences in the pharmacokinetics of ritonavir. 
Pharmacokinetic differences due to race have not been identified. 
Pediatric Patients: 
Steady-state pharmacokinetics were evaluated in 37 HIV-1 infected patients 
ages 2 to 14 years receiving doses ranging from 250 mg per m2 twice-daily to 400 mg 
per m2 twice-daily in PACTG Study 310, and in 41 HIV-1 infected patients ages 1 
month to 2 years at doses of 350 and 450 mg per m2 twice-daily in PACTG Study 
345. Across dose groups, ritonavir steady-state oral clearance (CL per F per m2) was 
approximately 1.5 to 1.7 times faster in pediatric patients than in adult subjects. 
Ritonavir concentrations obtained after 350 to 400 mg per m2 twice-daily in pediatric 
patients greater than 2 years were comparable to those obtained in adults receiving 
600 mg (approximately 330 mg per m2) twice-daily. The following observations were 
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seen regarding ritonavir concentrations after administration with 350 or 450 mg per 
m2 twice-daily in children less than 2 years of age. Higher ritonavir exposures were 
not evident with 450 mg per m2 twice-daily compared to the 350 mg per m2 twice-
daily. Ritonavir trough concentrations were somewhat lower than those obtained in 
adults receiving 600 mg twice-daily. The area under the ritonavir plasma 
concentration-time curve and trough concentrations obtained after administration with 
350 or 450 mg per m2 twice-daily in children less than 2 years were approximately 
16% and 60% lower, respectively, than that obtained in adults receiving 600 mg 
twice-daily. 
Renal Impairment: 
Ritonavir pharmacokinetics have not been studied in patients with renal 
impairment, however, since renal clearance is negligible, a decrease in total body 
clearance is not expected in patients with renal impairment. 
Hepatic Impairment: 
Dose-normalized steady-state ritonavir concentrations in subjects with mild hepatic 
impairment (400 mg twice-daily, n = 6) were similar to those in control subjects 
dosed with 500 mg twice-daily. Dose-normalized steady-state ritonavir exposures in 
subjects with moderate hepatic impairment (400 mg twice-daily, n= 6) were about 
40% lower than those in subjects with normal hepatic function (500 mg twice-daily, 
( n = 6). Protein binding of ritonavir was not statistically significantly affected by 
mild or moderately impaired hepatic function. No dose adjustment is recommended in 
patients with mild or moderate hepatic impairment. However, health care providers 
should be aware of the potential for lower ritonavir concentrations in patients with 
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moderate hepatic impairment and should monitor patient response carefully. Ritonavir 
has not been studied in patients with severe hepatic impairment. 
Microbiology: 
Mechanism of Action: 
Ritonavir is a peptidomimetic inhibitor of the HIV-1 protease. Inhibition of 
HIV protease renders the enzyme incapable of processing the gag-pol polyprotein 
precursor which leads to production of non-infectious immature HIV-1 particles. 
Antiviral Activity in Cell Culture: 
The activity of ritonavir was assessed in acutely infected lymphoblastoid cell 
lines and in peripheral blood lymphocytes. The concentration of drug that inhibits 
50% (EC50) value of viral replication ranged from 3.8 to 153 nM depending upon the 
HIV-1 isolate and the cells employed. The average EC50 for low passage clinical 
isolates was 22 nM (n = 13). In MT4 cells, ritonavir demonstrated additive effects 
against HIV-1 in combination with either didanosine (ddI) or zidovudine (ZDV). 
Studies which measured cytotoxicity of ritonavir on several cell lines showed that 
greater than 20 µM was required to inhibit cellular growth by 50% resulting in a cell 
culture therapeutic index of at least 1,000. 
Resistance: 
HIV-1 isolates with reduced susceptibility to ritonavir have been selected in 
cell culture. Genotypic analysis of these isolates showed mutations in the HIV-1 
protease gene encoding at amino acid substitutions I84V, V82F, A71V, and M46I. 
Phenotypic (n = 18) and genotypic (n = 48) changes in HIV-1 isolates from selected 
patients treated with ritonavir were monitored in phase I/II trials over a period of 3 to 
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32 weeks. Substitutions associated with the HIV-1 viral protease in isolates obtained 
from 43 patients appeared to occur in a stepwise and ordered fashion; in sequence, 
these substitutions were position V82A/F/T/S, I54V, A71V/T, and I36L, followed by 
combinations of substitutions at an additional 5 specific amino acid positions 
(M46I/L, K20R, I84V, L33F and L90M). Of 18 patients for whom both phenotypic 
and genotypic analysis were performed on free virus isolated from plasma, 12 showed 
reduced susceptibility to ritonavir in cell culture. All 18 patients possessed one or 
more substitutions in the viral protease gene. The V82A/F substitution appeared to be 
necessary but not sufficient to confer phenotypic resistance. Phenotypic resistance 
was defined as a greater than or equal to 5-fold decrease in viral sensitivity in cell 
culture from baseline. 
Cross-Resistance to Other Antiretroviral: 
Among protease inhibitors variable cross-resistance has been recognized. 
Serial HIV-1 isolates obtained from six patients during ritonavir therapy showed a 
decrease in ritonavir susceptibility in cell culture but did not demonstrate a concordant 
decrease in susceptibility to saquinavir in cell culture when compared to matched 
baseline isolates. However, isolates from two of these patients demonstrated 
decreased susceptibility to indinavir in cell culture (8-fold). Isolates from 5 patients 
were also tested for cross-resistance to amprenavir and nelfinavir; isolates from 3 
patients had a decrease in susceptibility to nelfinavir (6- to 14-fold), and none to 
amprenavir. Cross-resistance between ritonavir and reverse transcriptase inhibitors is 
unlikely because of the different enzyme targets involved. One ZDV-resistant HIV-1 
isolate tested in cell culture retained full susceptibility to ritonavir. 
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 NONCLINICALTOXICOLOGY:                                                     
Carcinogenesis, Mutagenesis, Impairment of Fertility: 
Carcinogenesis: 
Carcinogenicity studies in mice and rats have been carried out on ritonavir. In 
male mice, at levels of 50, 100 or 200 mg per kg per day, there was a dose dependent 
increase in the incidence of both adenomas and combined adenomas and carcinomas 
in the liver. Based on AUC measurements, the exposure at the high dose was 
approximately 0.3-fold for males that of the exposure in humans with the 
recommended therapeutic dose (600 mg twice-daily). There were no carcinogenic 
effects seen in females at the dosages tested. The exposure at the high dose was 
approximately 0.6-fold for the females that of the exposure in humans. In rats dosed at 
levels of 7, 15 or 30 mg per kg per day there were no carcinogenic effects. In this 
study, the exposure at the high dose was approximately 6% that of the exposure in 
humans with the recommended therapeutic dose. Based on the exposures achieved in 
the animal studies, the significance of the observed effects is not known. 
Mutagenesis 
Ritonavir was found to be negative for mutagenic or clastogenic activity in a battery 
of in-vitro and in vivo assays including the Ames bacterial reverse mutation assay 
using S.typhimurium and E. coli, the mouse lymphoma assay, the mouse micronucleus 
test and chromosomal aberration assays in human lymphocytes. 
Impairment of Fertility 
Ritonavir produced no effects on fertility in rats at drug exposures 
approximately 40% (male) and 60% (female) of that achieved with the proposed 
therapeutic dose. Higher dosages were not feasible due to hepatic toxicity. 
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                                           4.2. POLYMER PROFILE 
   4.2.1.HYDROXY PROPYL METHYL CELLULOSE 53 
Chemical Name: 
 Cellulose 2- hydroxy propyl methyl ether 






Cellulose, Hypromellose, 2 – Hydroxypropylmethyl ether, Methyl hydroxy 
propyl cellulose, Methocel, Pharmacoat, Metolose. 
Structure: 
 
Figure 6.Hydroxypropyl methylcellulose 
Chemical Name: 
 Cellulose 2- hydroxy propyl methyl ether 
 Mixed ether of cellulose with some of the hydroxyl groups in the form of 
methyl ether and some in the form of the 2-hydroxy propyl ether. Several grades of 
hydroxypropyl methylcellulose are distinguished by appending a number indicative of 
the apparent viscosity, in millipascal, of a 2% w/w solution measured at 20°C. 
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Hypromellose defined in the USP 25 specifies the substitution type by appending a 
four digit number to the nonproprietary name, e.g. hypromellose 1828. The first two 
digits refer to the approximate percentage content of the methoxy group (OCH3). The 
second two digits refer to the approximate percentage content of hydroxypropoxy 
group [OCH2 CH C (OH) CH3], calculated on a dried basis. Molecular weight is 
approximately 10,000 – 15, 00,000. 
Description: 
 It is a white, yellowish white or greyish white, practically odorless, fibrous 
powder or granules. 
Physical Properties 
Solubility:  
Soluble in cold water, forming a colloidal solution; practically insoluble in hot 
water, dehydrated alcohol, chloroform and ether.  
PH:  
 5.5 to 8.0. 
Melting Point: 
 Browns at 190-200°C; chars at 225-230°C; Tg is at 170-180°C. 
Bulk Density: 
 0.341 g/cm3 
Tapped Density: 
 0.557 g/cm3 
Enzyme Resistance: 
 Comparatively enzyme resistant 
Gel Formation:  
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Undergoes a reversible transformation from solution to gel upon heating and 
cooling respectively. 
Gel Point: 
 50 – 90°C depending upon the grade 
Ash Value: 
 1.5 – 3 % depending upon the grade 
Specific Gravity: 
    1.30 
Surface Activity: 
 Provides some surfactant activity in solutions, surface tension for such 
solutions range from 42 – 56 dynes/cm. 
Storage:  
Store in well-closed containers. 
Drug Excipients Interactions: 
 Hydroxy propyl methylcellulose is incompatible with some oxidizing agents. 
Safety: 
Hydroxy propyl methylcellulose is generally regarded as a nontoxic and 
nonirritant material although excessive oral consumption may have a laxative effect. 
Pharmaceutical Uses: 
 HPMC is widely used in oral and topical pharmaceutical formulations. It is used 
as tablet binder, for film coating and in sustained release preparations. Hypromellose 
is also used as a suspending and thickening agent in topical formulations, particularly 
ophthalmic preparations. It is also used as an emulsifier, suspending agent and 
stabilizing agent in topical gel and ointments. 
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   Baking soda; monosodium carbonate; sodium hydrogen carbonate; sodium 
acid carbonate 
IUPAC Name: 
   Carbonic acid monosodium salt 
Empirical Formula:  
     NaHCO3     
Molecular Weight: 
      84.01 
Description: 
   Sodium bicarbonate occurs as an odourless, white, crystalline powder with 
saline, slightly alkaline taste. 
Typical Properties: 
Density (bulk):      
       0.869 g/cm3 
Density (tapped): 
       1.369g/cm3 
Melting point: 
           270°C 
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Pharmaceutical Application: 
   Sodium bicarbonate is generally used in pharmaceutical formulations as a 
source of carbon dioxide in effervescent tablets and granules. It is also widely used to 
produce or maintain alkaline pH in preparation. In effervescent tablets and granules, 
sodium bicarbonate is usually formulated with citric and tartaric acid combinations of 
citric and tartaric acid often preferred in formulations as citric acid alone produces a 
sticky mixture that is difficult to granulate, while if tartaric acid is used alone granules 
lose firmness. Sodium bicarbonate is also used in tablet formulations to buffer drug 
molecules that are weak acids, thereby increasing the rate of tablet dissolution and 
reducing gastric irritation. Additionally, sodium bicarbonate is used in solutions as a 
buffering agent for erythromycin, lidocaine, local anaesthetic solutions. In some 
parenteral formulations (e.g. niacin), sodium bicarbonate is used to produce sodium 
salt of the active ingredient that has enhanced solubility. Sodium bicarbonate has also 
been used as a freeze drying stabilizer and in toothpastes. 
   Recently, sodium bicarbonate has been used as a gas forming agent in alginate 
raft systems and in floating, controlled release oral dosage forms of furosemide and 
cisapride. Therapeutically, sodium bicarbonate may be used as an antacid, and as the 
source of bicarbonate anion in a treatment of metabolic acidosis. Sodium bicarbonate 
may also be used as a component of oral rehydration salts and as a source of 
bicarbonate in dialysis fluids. 
Moisture content: 
 Below 80 % relative humidity, the moisture content is less than 1% w/w. 
above 85% relative humidity sodium bicarbonate rapidly absorbs water and may start 
to decompose with loss of carbon dioxide. 
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Incompabilities: 
 Sodium bicarbonate reacts with acids, acidic salt and many alkaloidal salts, 
with the evolution of carbon dioxide. In liquid mixtures containing bismuth 
subnitrate, sodium bicarbonate reacts with the acid formed by hydrolysis of bismuth 
salt. In solution, sodium bicarbonate has been reported to be incompatible with many 
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4.4. MICROCRYSTALLINE CELLULOSE53 
Nonproprietary Names:  
                                                  BP :        Microcrystalline Cellulose 
                                                   JP :         Microcrystalline Cellulose 
                                                   PhEur:    Cellulose, Microcrystalline 
                                                   USP-NF: Microcrystalline Cellulose 
 Synonyms: 
Avicel PH; Cellets; Celex; cellulose gel; hellulosummicrocristallinum; 
Celphere; Ceolus KG; crystalline cellulose; E460; Emcocel; Ethispheres; Fibrocel; 
MCC Sanaq; Pharmacel; Tabulose; Vivapur. 
Structural Formula: 
 
Chemical Name:  
        Cellulose [9004-34-6] 
 Formula and Molecular Weight: 
          (C6H10O5)n ,36 000 
where n is 220. 
 
Description: 
Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant. 
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Applications in Pharmaceutical Formulation or Technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes. In addition to its use as a 
binder/diluent, microcrystalline cellulose also has some lubricant and disintegrant 





















(Grade used PVP K30) 
Nonproprietary Names: 
                                                             
                                                            
                                                             
Synonyms:  
E 1201; Kollidon; Plasdone; poly [1




CAS Registry Number: 
[9003-39-8] 
Molecular Weight: 
  2500-3,000,000 
Functional Category: 
 Suspending agent, tablet binder. 
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. POLY VINYL PYRROLIDONE 
 
 
BP     :             Povidone.  
PhEur : Polyvidonum.  
USP   :  Povidone.  
-(2-oxo-1-pyrrolidinyl) ethylene]; 
-vinyl-2- pyrrolidinone polymer. 
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Description: 
Povidone is a fine, white to creamy-white colored, odorless or almost odorless, 
hygroscopic powder .Povidones with K values equal to or lower than 30 are  
manufactured by spray drying and exist as spheres. Povidone K 90 having higher k 
value  
povidones are manufactured by drum drying and exist as plates. 
Stability and Storage Conditions:  
Povidone darkens to some extent on heating at 1500C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110-1300C; 
steam sterilization of an aqueous solution does not alter its properties. Aqueous 
solutions are susceptible to mold growth and consequently require the addition of 
suitable preservatives.  
Povidone may be stored under ordinary conditions without undergoing decomposition 
or degradation. However, since the powder is hygroscopic, it should be stored in an 
airtight container in a cool, dry, place.  
Pharmacopoeial Specifications 
Test      USP XXII 
Identification+ 
                         pH       3.0 - 7.0 
                         Water    ≤ 5.0% 
                          Residue on ignition  ≤ 0.1% 
Sulfated ash - 
                        Lead   ≤ 10ppm 
Heavy Metals - 
                        Vinylpyrrolidone  ≤ 0.2% 
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K-value 
                 ≤ 15 85.0-115.0% 
                 > 15 90.0-108.0% 
 
Incompatibilities: 
Povidone is compatible in solution with a wide range of inorganic salts, 
natural and synthetic resins and other chemicals. It forms molecular adducts in 
solution with sulfathiazole, sodium salicylate, salicylic acid, Phenobarbital, tannin 
and other compounds. The efficiency of some preservatives, e.g. thimerosal, may be 
adversely affected by the formation of complexes with povidone.  
Typical Properties: 
Density:            1.17-1.18g/cm3 
Melting Point: Softens at 1500C.  
Solubility: 
Freely soluble in acids, chloroform, ethanol, ketones, methanol, and water; 
practically insoluble in ether, hydrocarbons and mineral oil. In water the 
concentration of a solution is limited only by the viscosity of the resulting solution 
which is function of the K-value.  
Safety: 
Reports of adverse reactions to povidone primarily concern the formation of 
subcutaneous granulomas at the injection site of intramascular injections formulated 
with povidone. Evidence also exists that povidone may accumulate in the organs of 
the body following intramascular injections.  
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Applications in Pharmaceutical Formulations: 
Although povidone is used in a variety of pharmaceutical formulations it is 
primarily used in solid dosage form. In tableting, povidone solutions are used as 
binder in wet granulation processes. Povidone is also added to powder blends in the 
dry form and granulated in situ by the addition of water, alcohol or hydroalcoholic 
solutions. Povidone solutions may also be used as coating agent.  
Povidone is additionally used as a suspending, stabilizing or viscosity-
increasing agent in a number of topical and oral suspensions and solutions. The 
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                                           4.6.MAGNESIUM STEARATE53 
Non-Proprietary Names: 
                                                                    BP:             Magnesium stearate;  
                                                                    IP:             Magnesium stearate 
                                                                    PhEur:        Magnesiistearas; 
                                                                     USPNF:     Magnesium stearate 
Synonyms:  
Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic acid, 
magnesium salt. 
Chemical Name and CAS Registry Number:  




        591.34 
The USP-NF describes magnesium stearate as a compound of magnesium with 
a mixture of solid organic acids that consists chiefly of variable proportions of 
magnesium stearate and magnesium palmitate (C32H62MgO4). The PhEur 2005 
describes magnesium stearate as a mixture of magnesium salts of different fatty acids 
consisting mainly of stearic acid and palmitic acid and in minor proportions other 
fatty acids. 
Structural Formula: 
        [CH3 (CH2)16COO]2Mg 
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Description: 
 Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odour of stearic acid and a 
characteristic taste. The powder is greasy to touch and readily adheres to the skin. 
Physical Properties  
Crystalline Forms: 
High-purity magnesium stearate has been isolated as a trihydrate, a dehydrate 
and an anhydrate. 
Density (bulk):   
0.159 g/cm3 
Density (tapped): 
  0.286 g/cm3 





 Poorly flowing, cohesive powder. 
Melting Range:  
117–150°C (commercial samples); 126–130°C (high purity magnesium 
stearate). 
Solubility: 
 Practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warmbenzene and warm ethanol (95%). 
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Specific Surface Area: 
  1.6–14.8 m2/g 
Stability and Storage Conditions:  
Magnesium stearate is stable and should be stored in a well-closed container in 
a cool, dry place. 
Pharmaceutical Application 
 Magnesium stearate is widely used in cosmetics, food and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
 
 
     
 
 
Chapter 4   Materials and Methods 
Department of Pharmaceutics                 JKKMMRF College of Pharmacy 79
4.7.TALC53 
Synonyms                  :        Purified French Chalk, Purtalc, Soapstone.  
Description          :  It is very fine, white to grayish-white colored odorless, 
impalpable, unctuous,crystalline powder.    
Functional categories  : Glidant and lubricant in tablets and  capsules. 
Solubility : Insoluble in water, organic solvent, dilute  
  Acid & alkalis. 
pH : 7.0 – 10.0  for a 20 % aqueous dispersion. 
Loss on drying             : < 1.0 % 
Hygroscopicity :  It absorbs insignificant amount of water at Relative                                   
humidities upto about 90 %.  
Stability and storage 
Conditions : It is a stable material. It should be stored in a Well-
closed container in a cool, dry place. 
 
Incompatibilities   : Incompatible with quaternary ammoniu Compounds 
Applications : It is widely used in oral solid dosage forms as a 
Lubricant & diluents.  It is used as a dusting  
   powder in topical use. Additionally used to  
   clarify liquids and mainly used in food and  
   cosmetics products because of its lubricant   
   properties. 
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4.7. Preformulation studies 
4.7.1.Determination of Melting Point. 
Melting point of Ritonavir was determined by capillary method. Fine powder 
of Ritonavir was filled in glass capillary tube (previously sealed on one end). The 
capillary tube is inserted into the melting point apparatus and observed the 
temperature at which drug started to melt by using the thermometer which was 
already immersed into the liquid paraffin in the apparatus. 
4.7.2.Compatibility study: 
          A successful formulation of a stable and effective solid dosage form depends on 
careful selection of the excipients that are added to facilitate administration, promote 
the consistent release and bioavailability of the drug and protect it from degradation. 
If the excipients are new and have not been used in formulations containing the active 
substance, the compatibility studies are of paramount importance. 
4.7.3.FT-IR: 
Compatibility of the Drug with the excipients was determined by subjecting 
the physical mixture of the drug and the polymers of the main formulation to infrared 
absorption spectral analysis. Any changes in chemical composition of the drug after 
combining it with the polymers were investigated with I.R. spectral analysis. 
 Schematic representation of compatibility studies 
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Procedure: 
Weighed amount of drug (3mg) was mixed with 100mg of potassium bromide (dried 
at 40-50oC). The mixture was taken and compressed under 10-ton pressure in a 
hydraulic press to form a transparent pellet. The pellet was scanned by IR 
spectrophotometer. 
4.7.4.Drug–Polymer Interaction/Compatibility study using FTIR  
Fourier Transfer Infrared Spectroscopy 
IR has been the method of choice to probe the nature and extent of 
interaction in polymer blends. IR was used in the study because mixing of the two 
components at molecular level will cause changes in oscillating dipoles of the 
molecules. If the drug and polymer interact then functional groups in FTIR spectra 
will show band shift and broadening compared to that of pure compounds. 
Method 
Potassium Bromide disc containing drug, polymer and their physical 
mixture were prepared to record the spectrum by using Shimadzu 8400S FTIR. 
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4.7.5.Standard Calibration Curve of Ritonavir 
Ritonavir was quantitatively analyzed by various techniques. In the present 
study, Ritonavir was estimated by UV spectrophotometry method.  
4.7.6. Determination of λmax for Ritonavir  
 stock solutions of drug sample were prepared by dissolving 100.0 mg of drug 
in 100.0 ml of 0.1 N HCl were further diluted and analyzed spectrophotometrically to 
determine λmax. 
Observation:  
The λmax was found to be 246 nm. 
Preparation of standard calibration curve of Ritonavir 0.1 N HCl 
A. Preparation of 0.1 N HCl: 
 8.5 ml of conc. hydrochloric acid was diluted upto 1000 ml with distilled 
water, gives 0.1 N HCl. 
B. Preparation of dilutions for standard curve: 
 Stock solution was prepared by dissolving 100.0 mg of Ritonavir in 
100.0 ml of 0.1 N HCl solutions, which was further diluted to give the 
solutions of concentration 2, 4, 6, 8 and 10µg/ml respectively. Absorbance of 
these solutions were measured on UV spectrophotometer at 246 nm and 
plotted against the concentration to give the standard curve. 
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Table No. 7: Composition of Ritonavir Floating matrix Tablets 
Slno Composition of       
ritonavir F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1 Ritonavir 100 100 100 100 100 100 100 100 100 100 
2 HPMC K4M 200 100 150 200 -- ---- ---- ----- ----- ----- 
3 HPMCK15M ---- ----- ----- ------ 100 150 200 ----- ----- ------ 
4 HPMCK100M ---- ----- ----- ------ ----- ------- ------ 100 150 200 
5 SODIUM BICARBONATE ----- 30 30 30 30 30 30 30 30 30 
6 MICROCRYSTALLINE CELLULOSE 
80 
 
150 100 50 150 100 50 150 100 50 
7 PVPK30 10 10 10 10 10 10 10 10 10 10 
8 MAGNESIUM STEARATE 5 5 5 5 5 5 5 5 5 5 
9 TALC 5 5 5 5 5 5 5 5 5 5 
 Total weight in mg 400 400 400 400 400 400 400 400 400 400 
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4.8.Formulation of Floating Tablets of  Ritonavir by Direct compression 
technique 
4.8.1.Preparation of Floating Tablets of Ritonavir 
Technology Applied: Direct compression technique 
The key ingredients included in the formulations are: 
 Hydrophilic Polymers: HPMC K4M, HPMC K15M, HPMCK100M to modify 
the pattern of drug release from matrix. 
 Effervescent agent: Sodium bicarbonate 
 Filler: Micro Crystalline Cellulose 
 Antiadherant: Talc 
 Lubricant: Magnesium Stearate. 
Procedure: 
 Floating tablets of each containing 100mg ritonavir drug  were prepared by 
direct compression technique.The composition of various formulations of the tablets 
with their codes were listed in the table. Accurately weighed quantities of polymer 
and MCC for each batch were taken in a mortar and mixed geometrically, to this 
required quantity of Ritonavir was added and mixed slightly with pestle. Accurately 
weighed quantity of Sodium bicarbonate, citric acid was taken separately in a mortar 
and powdered with pestle. The powder is passed through sieve no 40 and mixed with 
the ritonavir blend which was also passed through sieve no 40. The whole mixture 
was mixed for 3 minutes. To this Magnesium stearate was added and mixed for 
minutes, later Talc was added and mixed for 2 minutes. The composition of various 
formulations was given in above table.7 
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4.9.Evaluation of powder characteristics 
 Pre-Compression Parameters: 
 Angle of Repose 
 Angle of response is the angle of inclination, formed to the flat surface by 
the bulk of granules when it is allowed to flow under gravitational force from a fixed 
height.  It is a characteristic of granule flow properties and is calculated by using the 
formula. 
                θ = tan -1 (h/r) 
Where  
θ - Angle of repose 
h - Height of granule above flat surface 
r - Radius of circle formed by the granule pile  
Bulk Density: 
 The bulk density was determined by pouring perceived drug excepient 
blend into a graduated cylinder and measuring the volume and weight. It is expressed 
in g/ml and is given by 
                                             Db = M/Vo 
Where 
                     M is the mass of powder  
                     Vo is the bulk volume of powder 
Tapped density: 
 It was determined by placing a graduated cylinder containing a known mass 
of drug excipients blend, on mechanical tapping apparatus.The tapped volume was 
measured by tapping the powder to constant volume is expressed in g/ml. and is given 
by 
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    Dt = M/Vt 
 
Carr’s Compressibility Index 
It is also a characteristic of granule flow properties. The bulk density and 
tapped density was measured and compressibility index was calculated using the 
formula,  
   C.I. = { (Pt– P0 ) / Pt } × 100 
Where, Pt = tapped density 
Ρ0                                  = bulk density 
Hausner’s Ratio 
Tapped density and bulk density were measured and the hausner ratio was 
calculated using the formula,  
                         Hausner ratio = Pt/ P0 
Where,  Pt = tapped density 
              Ρ0       = bulk density 
Determination of Drug Content : 
 Twenty tablets were taken ,powdered and the powder equivalent to one dose 
each was transferred to a 100 ml of volumetric flask and 0.1N Hcl was added .The 
volume was then made up to the mark with 0.1N HCl .The solution was filtered and 
diluted  and the samples was estimated by using U V.Visible Spectro photometer  at 
lamda max of 276nm. 
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4.10.Evaluation of Tablets 
Hardness test 
Tablet hardness has been defined as the force required for breaking a tablet in 
a diametric compression test.  A tablet was placed between two anvils of the hardness 
tester (Monsanto type), force was applied to the anvils, and the crushing strength that 
caused the tablet to break was recorded. 
Friability test 
Tablets require a certain amount of strength, or hardness and resistance to 
friability, to withstand mechanical shocks of handling in manufacture, packaging and 
shipping.  Preweighed tablet samples (20 tablets) were placed in the friabilator, which 
was then operated for 100 revolutions, dropping the tablets a distance of 6 inches with 
each revolution.  The percentage friability was calculated using the formula. 
% friability = 100x
weight initial
weight finalweight initial −
 
Weight variation test  
20 tablets were selected at random and weighted individually. The average 
weight of each batch of tablet was calculated. Individual weights of the tablets were 
compared with the average weight.  Since the tablets weighed over 100 mg, I.P. 
specifies that the tablets pass the test if not more than two of the individual weights 
deviate from the average weight by more than 5%. 
Determination of Drug content  
To evaluate tablets potential for efficacy, the amount of drug per tablet needs 
to be monitored from tablet to tablet, and batch to batch.  To perform the test, ten 
tablets from each batch were weighed and powdered. Powder equivalent to the 
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average weigh of the tablet was accurately weighed and transferred into a 100 ml 
volumetric flask and dissolved in a suitable quantity of distilled water. The solution 
was made up to the mark and mixed well. A portion of the sample was filtered and 
analyzed by a UV spectrophotometer at 246nm. 
In-vitro buoyancy Study: 
The time taken for dosage form to emerge on surface of medium called 
floating lag time (FLT) and duration of time by which the dosage form constantly 
emerge on surface of medium called total floating time.(TFT). 
Procedure 
The randomly selected tablets from each formulation were kept in a 100ml 
beaker containing simulated gastric fluid,pH 1.2 as per USP.The temperature of 
medium was maintained at 37±2 oC. the time taken for tablet to emerge on surface of 
medium and the duration of time by which the tablet constantly remain on surface of 
medium was noted. 
 
                 At initial time                                                 After 5min 
Fig. 12: Floating behavior of Ritonavir Floating Tablet (F7) 
Chapter 4 Materials and Methods 
 







4.11.Water Uptake Studies: 
 Study of Swelling behaviour 
Swelling of tablet excipients particles involves the absorption of a liquid 
resulting in an increase in weight and volume. Liquid uptake by the particle may be 
due to saturation of capillary spaces within the particles or hydration of 
macromolecule. The liquid enters the particles through pores and bind to large 
molecule, breaking the hydrogen bond and resulting in the swelling of particle. The 
extent of swelling can be measured in terms of % weight gain by the tablet. 
 
In-vitro Dissolution Study: 
Dissolution of the tablet of each batch was carried out using USP type I 
apparatus (Basket type). 
Procedure 
Nine 100 ml of 0.1 N HCl was filled in a dissolution vessel and the 
temperature of the medium was set at 37±2oC. Tablet was placed in each dissolution 
vessel and rotational speed of basket was set at 50 rpm. The 5 ml of sample was 
withdrawn at predetermined time interval for 12 hours and same volume of fresh 
medium was replaced. The samples were analyzed for drug content against 0.1 N HCl 
as blank at λ max of 246 nm using double beam UV visible spectrophotometer. The 
content of drug was calculated using the equation generated from standard curve. The 
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4.12 Study of drug release kinetics: 
 The analysis of drug release mechanism from a pharmaceutical dosage from is 
an important but complicated process and is practically evident in the case of matrix 
systems. As a model-dependent approach, the dissolution data was fitted to five 
popular release models such as zero-order, first-order, diffusion and exponential 
equations, which have been described in the literature. The order of drug release from 
matrix systems was described by using zero order kinetics or first orders kinetics. The 
mechanism of drug release from matrix systems was studied by using Higuchi 
equation, erosion equation and Peppas-Korsemeyer equation. The results are given in 
Table 26. 
 
Zero Order Release Kinetics: 
It defines a linear relationship between the fraction of drug released versus 
time. 
Q = kot 
 
 
 Where, Q is the fraction of drug released at time t and kois the zero order 
release rate constant. 
 A plot of the fraction of drug released against time will be linear if the release 
obeys zero order release kinetics. 
 
First Order Release Kinetics: 
 Wagner assuming that the exposed surface area of a tablet decreased 
exponentially with time during dissolution process suggested that drug release from 
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most of the slow release tablets could be described adequately by apparent first-order 
kinetics. The equation that describes first order kinetics is 
In (1-Q) = - K1t 
Where, Q is the fraction of drug released at time t and k1 is the first order release rate 
constant. 
 Thus, a plot of the logarithm of the fraction of drug remained against time will 
be linear if the release obeys first order release kinetics. 
 
Higuchi’s equation: 
  It defines a linear dependence of the active fraction released per unit of 
surface (Q) on the square root of time. 
        Q=K2t½ 
 
Where, 
                    K2 is the release rate constant. 
A plot of the fraction of drug released against square root of time will be linear if the 
release obeys Higuchi equation. This equation describes drug release as a diffusion 
process based on the Fick’s law, square root time dependant. 
 
Power Law: 
 In order to define a model, which would represent a better fit for the 
formulation, dissolution data was further analyzed by Peppas and Korsemeyer 
equation (Power Law). 
Mt/Mα = K.tn  
Where, Mt is the amount of drug released at time t and Mα is the amount released at 
time α, thus the Mt/Mαis the fraction of drug released at time t,k is the kinetic 
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constant and n is the diffusional exponent. To characterize the mechanism for both 
solvent penetration and drug release n can be used as abstracted in Table-6. A plot 
between log of Mt/Mα against log of time will be linear if the release obeys Peppas 
and Korsemeyer equation and the slope of this plot represents “n” value. 
Table 8: Diffusion exponent and solute release mechanism for cylindrical shape 
Diffusion Exponent Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anomalous (non-fickian) diffusion 
0.89 Case II transport 
n>0.89 Super Case II transport 
 
4.13. Stability Studies:[29] 
Introduction 
The purpose of stability testing is to provide evidence on how the quality of an active 
substance or pharmaceutical product varies with time under the influence of a variety 
of environmental factors such as temperature, humidity, and light. In addition, 
product-related factors influence the stability, e.g. the chemical and physical 
properties of the active substance and the pharmaceutical excipients, the dosage form 
and its composition, the manufacturing process, the nature of the container-closure 
system, and the properties of the packaging materials. Also, the stability of excipients 
that may contain or form reactive degradation products, have to be considered. 
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Table- 9: Objectives of Stability Testing: 
OBJECTIVE TYPE OF STUDY USE 
To select adequate (from the 




Development of the 
product 




Development of the 
product and of the 
registration dossier 
To substantiate the claimed shelf-
life 
Real-time Registration dossier 
To verify that no changes have 
been introduced in the 
formulation or manufacturing 
process that can adversely affect 
the stability of the product 
Accelerated and 
real- time 
Quality assurance in 
general, including quality 
control. 
 
Climatic Zones and Conditions 
WHO has issued guidelines, where it is stated that the world is divided into four zones 
based on the prevailing annual climatic conditions for the purpose of stability testing. 
Zone I: temperate 
Zone II: subtropical with possible high humidity 
Zone III: hot/dry 
Zone IV: hot/humid 
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Measured data in the 
Open Air 
Measured data in storage 
room 



























So for example if a manufacturer plans to sell his products in zone-III he/she should 
do real time studies at 30oC and 35%RH.If a manufacturer wants to apply for the 
registration of a new drug, i.e. if he is applying for a (1) Investigative New Drug 
Application (IND) or (2) New Drug Application (NDA) or (3) Abbreviated New Drug 
Application (ANDA) then he has to assure the FDA regarding the drug’s/drug 
product’s safety, quality and efficacy. For this he has to carry out stability tests and 
submit stability data. How he should do this is specified by Q1A (R2). 
 
Selection of Batches 
Data from formal stability studies should be provided on at least three primary 
batches of the drug substance. These batches should be made to a minimum of pilot 
scale by the same synthetic route as that of the production batches. 
Specifications which include testing methods and acceptance criteria should be fixed. 
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Testing frequency in Months 
Long term:    0, 3, 6, 9, 12, 18, 24 
Accelerated storage:   0, 3, 6 
Storage conditions recommended 
Table-11 : Testing frequency for different storage conditions 
Study Storage condition Minimum time period 
covered by data at 
submission 
Long term* 250C + 20C/60% RH + 5% RH or 
300C + 20C/65% RH + 5% RH 
12 months 
Intermediate** 300C + 20C/65% RH + 5% RH 6 months 
Accelerated 400C + 20C/75% RH + 5% RH 6 months 
* It is up to the applicant to decide whether long term stability studies are performed 
at 25 + 2oC/60% RH + 5% RH or 30 0C + 2oC/65% RH + 5% RH.  
** If 30oC + 2oC/65% RH + 5% RH is the long-term condition, there is no 
intermediate condition.  
If long-term studies are conducted at 25oC+ 2oC/60% RH + 5% RH and “significant 
change” occurs at any time during 6 months’ testing at the accelerated storage 
condition, additional testing at the intermediate storage condition should be conducted 
and evaluated against significant change criteria (ICH, 2003) 
“Significant change” for a drug substance is defined as failure to meet is specification. 
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Table -12 : Drug substances intended for storage in a refrigerator 
Study Storage condition 
Minimum time period 
covered by data at 
submission 
Long term 50C + 30C 12 months 
Accelerated 250C + 20C/60% RH + 5% RH 6 months 
 
Table-13 : Drug substances intended for storage in a freezer 
Study Storage condition 
Minimum time period covered 
by data at submission 
Long term 200C + 50C 12 months 
 
Stability Testing for Established Drug Substances: 
WHO has issued guidelines for stability testing of pharmaceutical products 
containing well established drug substances in conventional dosage form. The 
stability of finished pharmaceutical products depends on environmental factors and on 
product related factors. So stability considerations should be given, the highest 
priority in the design and formulation of a product. The shelf life should be 
established with due regard to the climatic zones. To ensure both patient safety and 
the rational management of drug supplies, it is important that the expiry date and 
storage conditions are properly indicated on the label. 
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Accelerated stability testing: 
These are the studies designed to increase the rate of chemical degradation and 
physical change of a drug by using exaggerated storage conditions as part of the 
formal stability testing programme. The data thus obtained, in addition to those 
derived from real – time stability studies, may be used to assess longer – term 
chemical effects under non-accelerated conditions and to evaluate the impact of short-
term excursions outside the label storage conditions, as might occur during shipping. 
The results of accelerated testing studies are not always predictive of physical 
changes. These are also known as stress testing studies. 
 
Expiry date: 
The date given on the individual container of a drug product up to and 
including which the product is expected to remain within specifications if stored 
correctly. It is established for each batch by adding the shelf-life period to the date of 
manufacture. 
Real time (Long term) stability studies: 
Experiments on the physical, chemical, biological, biopharmaceutical and 
microbiological characteristics of a drug, during and beyond the expected shelf life 
and storage periods of samples under the storage conditions expected in the intended 
market. The results are used to establish the shelf life, to confirm the projected shelf 
life and to recommend storage conditions. 
Stability tests: 
A series of tests designed to obtain information on the stability of a 
pharmaceutical product in order to define its shelf-life and utilization period under 
specified packaging and storage conditions. 
Chapter 5 Results And Discussion 
Department of Pharmaceutics JKKMMRF College of pharmacy 
 
98
5. RESULTS AND DISCUSSION 
5.1 Preformulation study: 
5.1.1. Organoleptic Properties:  
Organoleptic Properties for Ritronavir was done as per IP specification and the 
result was given in the below table.14 
Table.14: Study of Organoleptic properties of Ritronavir 
Test Specification of IP Results 




Solubility test for Ritronavir was done as per IP specification and the result 
was given in the below table.15 
Table.15: Study of Solubility properties of Ritronavir 
Test Specification of IP Results 
Solubility It is freely soluble in 
methanol and ethanol, 
soluble in isopropanol and 
practically insoluble in 
water. 
 
Soluble in Alcohol, 
Ethanol, Methanol and 
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5.1.3. Melting point:  
Melting point for Ritronavir was done as per IP specification and the result 
was given in the below table.17 
Table.17: Study of Melting point properties of Ritronavir 
Test Specification of IP Results 
Melting Point 1200C – 1220C 121.20C 
 
Discussion:  
Preformulation studies indicate that the drug Ritonavir passes the 
identification test specified in IP. The physical parameters of drug as well as 
excipients concluded that these were considerably good to formulate the tablet by 
direct compression technique.  
5.1.4. IR spectra: 
 IR spectra for Ritronavir was done as per IP specification and the result was 
given in the below table.16 
Table.16. Study of IR spectra properties of Ritronavir: 
Test Specification of IP Results 
IR Spectra The potassium bromide 
disc contain drug was 
prepared to record the 
spectrum by using FTIR 
spectrophotometer 
The spectrum showed all 
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5.1.5. Drug–Polymer Interaction/Compatibility study using FTIR 
The FTIR spectra of the pure drug showed significant bands atcm3131, 3417, 
2301, 1715, 1527cm-1 which indicates the presence of hydroxyl, ether stretching, 
tertiary amine salt, carbonyl groups and phenyl nucleus skeletal stretching 
respectively. The different peaks of drug, polymer and their physical mixture indicate 
all groups and characteristics of the drug were not altered. There is no significant 















                          Graph No.1: FTIR Spectral 
Graph No.2: FTIR spectral analysis of Physical mixture of Drug a
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Graph No.3: FTIR spectral analysis of Physical mixture of Drug a
Graph No.4: FTIR spectral 
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nd polymer 
(Ritonavir +HPMC K15M) 
 
analysis of Physical mixture of Drug and polymer 













Graph No.6: FTIR spectral analysis of Physical mixture of 
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nd polymer 
(Ritonavir +Microcrystalline cellulose) 
 
 
Drug and polymer 
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 Physical mixture of drug and polymer was characterized by FTIR spectral 
analysis (Graph 1, 2, 3, 4, 5 and 6) for any physical as well as chemical alteration of 
drug characteristics. From results, it was concluded that there was no interference in 
the functional group as the principle peaks of Ritonavir were found to be unaltered in 
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Graph 7:  Lambda max of Ritonavir 
 
Chapter 5 Results And Discussion 










Chapter 5 Results And Discussion 
Department of Pharmaceutics JKKMMRF College of pharmacy 107
5.2. Standard Calibration Curve of Ritonavir 




From the scanning of drug in 0.1 N HCl, it was concluded that the drug had 
λmax of 246.0 nm and which was exactly similar as reported. From the standard curve 
of 0.1 N HCl it was observed that the drug obeys Beer – Lambert’s law in 










































Standard plot of 
Ritonavir
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5.3. Pre formulation studies: 
Table No. 18: Study of Characteristics of Final blend 
 
Discussion: 
Table.18 indicates the powder characteristics of various batches of floating 
tablets. Various formulations show good flow properties. Results of Angle of repose 





















F1 170.10′ 0.372 0.400 7 1.075 
F2 210.40′ 0.345 0.388 11 1.124 
F3 190.20′ 0.311 0.360 13.6 1.157 
F4 170.30′ 0.266 0.302 11.9 1.135 
F5 200.70′ 0.223 0.258 13.5 1.156 
F6 180.30′ 0.274 0.320 14.3 1.167 
F7 210.20′ 0.341 0.374 8.82 1.096 
F8 200.10′ 0.277 0.320 13.4 1.155 
F9 220.50′ 0.270 0.320 14.62 1.185 
F10 220.10′ 0.279 0.321 15.58 1.150 
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index (7 – 15.58) and Hausner’s ratio (1.075-1.185) shows satisfactory results, which 
is required for better bioavailability. 
5.4. Physical Properties 











F1 396±5 16.0 0.285 99.09 
F2 394±5 16.3 0.223 97.18 
F3 394±5 16.2 0.286 99.29 
F4 394±5 17.2 0.230 96.10 
F5 395±5 16.8 0.231 97.26 
F6 393±5 16.5 0.239 98.81 
F7 395±5 16.2 0.291 99.96 
F8 398±2 16.4 0.228 97.49 
F9 393±5 16.3 0.229 97.56 
F10 393±5              16.8 0.291 98.99 
 
Discussion:  
From the physical parameters (Table 19) of each batch, it was concluded that 
the tablets of all batches had desirable physical characteristics. Results of Hardness of 
various batches of prepared formulations (16.0 –17.2kg / sq cm.) and Friability (0.223 
– 0.291 %) indicates that the tablets having sufficient strength to withstand physical 
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abrasion. Tablets of all batches pass the weight variation test as per the limits 
prescribed in IP. (5% deviation is allowed for average weight of tablet X ≥ 250 mg). 
 
5.4.1. In-vitro Buoyancy study: 
Table 20: In-vitro Buoyancy study of Ritonavir Floating Tablets 
Batch Code Floating Lag Time(sec) Total Floating Time (Hours) 
F1             Did not float           Did not float 
F2 14 >5 
F3 17 >7 
F4 24 >9 
F5 16 >12 
F6 21 >12 
F7 14 >12 
F8 10 >12 
F9 12 >12 
F10 17 >12 
 
Discussion: 
 The Initial batch is prepared without sodium bicarbonate did not show any 
sign of floating. Therefore, sodium bicarbonate was used as a gas generating agent in 
order to float the tablet. The sodium bicarbonate induces Co2 generation in the 
presence of dissolution medium (0.1N Hcl). The gas generated is trapped and 
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protected within the gel formed by hydration of the polymer, thus decreasing the 
density of the tablet below 1gm/ml, and the tablet become buoyant. To study the 
effect of sodium bicarbonate concentration on floating lag time batches F1 to F10 
were selected. Sodium bicarbonate 30 mg was essential to achieve optimum in-vitro 
buoyancy (i.e floating lag time of 14-24 seconds and floating duration of 12 hrs). It 
was observed that floating lag time for this system in the range of 14 to 24 sec’s and 
flotation was achieved maximum at gas generating quantity of 30 mg with in 14 min. 
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5.4.2. Water Uptake Studies 
Table No. 21: Study of swelling characteristics of floating tablets of Ritonavir 
Batch Code 
Time in hrs. (% Swelling) 
2 4 6 8 
F1 56.75 83.70 72.98 74.06 
F2 46.85 90.88 67.43 66.23 
F3 64.47 74.63 70.38 72.01 
F4 63.98 67.74 76.41 63.59 
F5 90.61 122.12 84.70 70.67 
F6 57.84 72.25 71.10 60.65 
F7 54.87 72.21 69.34 64.04 
F8 53.57 66.79 65.5 60.63 
F9 62.79 94.94 86.50 80.43 
F10 59.13 67.40 81.15 80 
 
Discussion:  
Water uptake (swelling) study, Table No.21 cleared that order of swelling 
observed in these polymers could indicate the rates at which the preparations are able 
to absorb water and swell. Maximum liquid uptake and swelling of polymers were 
achieved after 4-8 hrs. The swelling index was calculated with respect to time. As the 
time increases, the swelling index was increased, because weight gain by the tablet 
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was increased proportionally with rate of hydration. Later on, it decreased gradually 
due to dissolution of outer most gelled layer of tablet into dissolution medium.  
 
5.4.3. In-Vitro Dissolution Study 





F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1 1 20.67 21.78 19.10 22.79 20.89 20.10 21.11 20.15 21.90 22.02 
2 2 38.85 39.67 34.12 36.45 34.56 36.29 35.21 37.56 37.78 37.89 
3 4 49.76 48.89 46.76 45.80 46.78 49.38 48.49 48.94 49.09 49.59 
4 6 54.58 55.69 57.37 52.79 54.50 56.12 57.50 58.10 58.78 58.81 
5 8 69.89 71.76 70.15 69.90 69.78 70.59 69.71 69.07 69.56 69.89 
6 10 75.76 85.91 87.71 80.15 82.51 81.19 82.45 83.19 83.57 83.96 
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Graph No. 10: In-Vitro Dissolution Profile of F5-F10 
 
Discussion: 
Table 23, indicates the dissolution data of various batches of floating tablets. The 
percentage drug release from batch F1 to F10 vary from 88.29 to 92.94%. In 
formulations F2 to F4 HPMC K4M were showed 91.07%, 91.99%, 92.67% at the end 
12th hour and formulations. From F5 to F7 (HPMC K15M) were showed the results as 
91.99%, 92.67%, 92.94 and from formulations F8 to F10 (HPMC K100M) shows the 
results 91.96%, 92.74% and 92.89%.Incomparison of F7 &  F10, F7 shows highest 
percentage drug release i.e. with HPMC K15M. Formulation F7 is selected as 
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release at the end of 12 hours as shown in graph 10. Formulation F7 is selected as 
optimized formulation because of using hydrophilic polymer HPMC K15M Among all 
formulations K15M grade provided better controlled release characteristics with 
excellent drug release and in-vitro buoyancy. From the above results, it was also 
evident that at higher viscosity grades of polymer concentrations, the rate of drug 
release was retarded greatly. 
. 
5.5. Study of drug release kinetics:  








Peppas Best fit 
Model 
R R R R N 
F1 0.889 0.954 0.970 0.955 0.652 Higuchi 
F2 0.895 0.962 0.963 0.997 0.850 peppas 
F3 0.938 0.957 0.978 0.989 0.824 peppas 
F4 0.905 0.939 0.970 0.984 0.824 peppas 
F5 0.925 0.943 0.981 0.998 0.814 peppas 
F6 0.915 0.934 0.985 0.995 0.726 peppas 
F7 0.921 0.935 0.990 0.998 0.703 peppas 
F8 0.906 0.948 0.982 0.991 0.697 peppas 
F9 0.904 0.941 0.985 0.990 0.684 peppas 
F10 0.903 0.941 0.984 0.991 0.692 peppas 
 
Discussion: 
  Table 23 indicates the release kinetics of floating tablets of Ritonavir. 
Dissolution data of batch F7 were subjected to treatment with different kinetics 
equations, which showed the release patterns. 
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Graph No: 14 Peppas Koresmeyer‘s plot 
 
Discussion: 
 Regression co-efficient value (R2) and n values for all formulation were 
shown in table 24. The release profile of the optimized formula F7 fitted best to 
Korsemeyer’s plot with R2 value of 0.999. As the n value for the Korsmeyer-Peppas 
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5.6 Determination of stability study of an optimised formulation:  
Table.24. Stability studies of ritonavir floating tablets. 
Parameters After 15 days After 30 days After 45 days 
Physical appearance No change  No change  No change  
Weight variation (mg)  395±1.6 395±2.70  395±1.30  
Hardness (kg/cm2) 16.2±0.23 16.32±0.64  16.32±0.99  
Friability (%)  0.291±0.05 0.291±0.08  0.30±0.06  
Drug content (mg/Tab)  99.91±0.34 98.99±0.29  98.90±0.87  
Buoyancy lag time (sec) 14±1.60  14±2.8  14±3.10  
Duration of Buoyancy (Hours)  >12 >12  >12  
 
Discussion: 
 According to ICH guidelines, 45 days stability study at 40C ±20C, 270C 
±20C and 450C ±20C for 45 days at RH 75±5% of optimized formulation (F7) was 
carried out. It showed negligible change over time for parameters like appearance, 
drug content, dissolution and assay etc., No significant difference in the drug content 
between initial and formulations stored at 40C ±20C, 270C ±20C and 450C ±20C for 45 
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6. SUMMARY& CONCLUSION 
In the present work attempts have been made to formulate floating tablets of 
Ritonavir with HPMC K4M, HPMC K15M, HPMC100M, by direct compression 
method by taking single polymer in the formulation. Ritonavir has shown high 
solubility in 0.1 HCl, therefore it was considered as a good candidate for gastro 
retentive dosage form  
  Ritonavir is used for the treatment of HIV which has a short elimination half-
life of 3-5 hours. Its dose is 100 to 400 mg/day orally in 1 or 2 divided doses. Because 
of frequent administration and short elimination half-life, Ritonavir is considered as 
an ideal drug for designing a sustained release formulation.  
 Floating tablets were developed to prolong the gastric residence time and 
increase drug bioavailability. 
 Ritonavir was chosen as a model drug because it is poorly absorbed from the 
lower gastrointestinal tract. 
 FTIR studies concluded that there were no interaction between drug and 
polymer. 
 Tablets were prepared by direct compression technique, using polymers such 
as HPMC K4M, K15M, K100M, and other standard excipients. According to 
this formulation codes F1, F2, F3, F4, F5, F6, F7, F8, F9, and F10 were 
prepared. 
 Tablets were evaluated for physical properties, viz. hardness, friability, weight 
variation, in-vitro Buoyancy and Swelling studies etc. Further, tablets were 
evaluated for in vitro release characteristics for 12 hrs. Drug release kinetics 
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6.1. CONCLUSION 
 From the above study it can be concluded that promising controlled release by 
gastro retentive floating tablets of Ritonavir was developed using different ratios of 
HPMC K4M, K15M and K100M 
 The floating tablet of Ritonavir was capable of maintaining plasma drug 
concentration through 12 hrs. 
 The formulation F7 was selected as an optimized formulation because it gave 
the best result in terms of the required in-vitro buoyancy study, good floating 
integrity and drug release in sustained release manner.  
 The release profile of the optimized formula, fitted best to Zero order kinetics 
with R2 value of 0.999.  
 As the n value for the Korsmeyer-Peppas model was found to be less than 
0.698, it follows Non fickian type of transport.  
 Short-term stability studies indicated no appreciable changes in the drug 
content and In-vitro drug release rates of formulation F7. 
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